{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:21:08Z","timestamp":1793395268089,"version":"4.5.0"},"reference-count":482,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02770-w","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:02:34Z","timestamp":1788134554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PI3K\/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation"],"prefix":"10.1038","volume":"11","author":[{"given":"Qingmiao","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2770_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku, F., Yap, T. A. & Meric-Bernstam, F. Targeting the PI3K pathway in cancer: are we making headway? Nat. Rev. Clin. Oncol. 15, 273\u2013291 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2770_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi, S. & Munirajan, A. K. Akt in cancer: mediator and more. Semin. Cancer Biol. 59, 80\u201391 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","volume":"20","author":"B Bilanges","year":"2019","unstructured":"Bilanges, B., Posor, Y. & Vanhaesebroeck, B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell Biol. 20, 515\u2013534 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2770_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman, D. A. et al. The PI3K pathway in human disease. Cell. 170, 605\u2013635 (2017).","journal-title":"Cell."},{"key":"2770_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer. 22, 138 (2023).","journal-title":"Mol. Cancer."},{"key":"2770_CR6","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1042\/BCJ20170258","volume":"474","author":"RR Dev","year":"2017","unstructured":"Dev, R. R. et al. Cytosine methylation by DNMT2 facilitates stability and survival of HIV-1 RNA in the host cell during infection. Biochem. J. 474, 2009\u20132026 (2017).","journal-title":"Biochem. J."},{"key":"2770_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075\u20131083 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2770_CR8","doi-asserted-by":"publisher","first-page":"103302","DOI":"10.1016\/j.redox.2024.103302","volume":"75","author":"B Sun","year":"2024","unstructured":"Sun, B. et al. FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. Redox Biol. 75, 103302 (2024).","journal-title":"Redox Biol."},{"key":"2770_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503434","volume":"12","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. C1q(+) macrophage-tumor cell interaction promoted tumorigenesis via GPR17\/PI3K\/AKT pathway induced DNA hypermethylation in nasopharyngeal carcinoma. Adv. Sci. 12, e2503434 (2025).","journal-title":"Adv. Sci."},{"key":"2770_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01225-x","volume":"21","author":"A Maharati","year":"2023","unstructured":"Maharati, A. & Moghbeli, M. PI3K\/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Commun. Signal. 21, 201 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2770_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara, J. A. et al. PI3K\/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193\u2013204 (2004).","journal-title":"Cancer Treat. Rev."},{"key":"2770_CR12","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra, V. et al. NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022\u20138030 (2008).","journal-title":"Cancer Res."},{"key":"2770_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","volume":"79","author":"M Song","year":"2019","unstructured":"Song, M., Bode, A. M., Dong, Z. & Lee, M. H. AKT as a therapeutic target for cancer. Cancer Res. 79, 1019\u20131031 (2019).","journal-title":"Cancer Res."},{"key":"2770_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/pharmaceutics13081195","volume":"13","author":"NM Roudsari","year":"2021","unstructured":"Roudsari, N. M. et al. Inhibitors of the PI3K\/Akt\/mTOR pathway in prostate cancer chemoprevention and intervention. Pharmaceutics. 13, 1195 (2021).","journal-title":"Pharmaceutics."},{"key":"2770_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s13402-020-00514-8","volume":"43","author":"Y Xiao","year":"2020","unstructured":"Xiao, Y. et al. The PI3K\/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. Cell. Oncol. 43, 669\u2013680 (2020).","journal-title":"Cell. Oncol."},{"key":"2770_CR16","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41418-025-01501-y","volume":"23","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. p53 transcriptionally activates DCP1B to suppress tumor progression and enhance tumor sensitivity to PI3K blockade in non-small cell lung cancer. Cell Death Differ. 23, 1722\u20131733 (2025).","journal-title":"Cell Death Differ."},{"key":"2770_CR17","doi-asserted-by":"publisher","first-page":"115615","DOI":"10.1016\/j.bcp.2023.115615","volume":"213","author":"J Man","year":"2023","unstructured":"Man, J. et al. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K\/AKT\/mTOR signaling pathway. Biochem. Pharmacol. 213, 115615 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"2770_CR18","doi-asserted-by":"publisher","first-page":"126913","DOI":"10.1016\/j.chemosphere.2020.126913","volume":"255","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. Effect and mechanism of PI3K\/AKT\/mTOR signaling pathway in the apoptosis of GC-1 cells induced by nickel nanoparticles. Chemosphere. 255, 126913 (2020).","journal-title":"Chemosphere."},{"key":"2770_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412123","volume":"12","author":"Q Yao","year":"2025","unstructured":"Yao, Q. et al. METTL3 potentiates M2 macrophage-driven MMT to aggravate renal allograft fibrosis via the TGF-\u03b21\/Smad3 pathway. Adv. Sci. 12, e2412123 (2025).","journal-title":"Adv. Sci."},{"key":"2770_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","volume":"17","author":"R Katso","year":"2001","unstructured":"Katso, R. et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615\u2013675 (2001).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"2770_CR21","doi-asserted-by":"publisher","first-page":"217112","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 598, 217112 (2024).","journal-title":"Cancer Lett."},{"key":"2770_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"B Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329\u2013341 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2770_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/42648","volume":"387","author":"A Toker","year":"1997","unstructured":"Toker, A. & Cantley, L. C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature. 387, 673\u2013676 (1997).","journal-title":"Nature."},{"key":"2770_CR24","doi-asserted-by":"publisher","first-page":"101430","DOI":"10.1016\/j.gendis.2024.101430","volume":"12","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Rozen, V., Zhao, Y. & Wang, Z. Oncogenic activation of PI K3 CA in cancers: emerging targeted therapies in precision oncology. Genes Dis. 12, 101430 (2025).","journal-title":"Genes Dis."},{"key":"2770_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer. 15, 7\u201324 (2015).","journal-title":"Nat. Rev. Cancer."},{"key":"2770_CR26","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/annonc\/mdw264","volume":"27","author":"ZB Mei","year":"2016","unstructured":"Mei, Z. B. et al. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann. Oncol. 27, 1836\u20131848 (2016).","journal-title":"Ann. Oncol."},{"key":"2770_CR27","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6, 1090\u20131105 (2016).","journal-title":"Cancer Discov."},{"key":"2770_CR28","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.ajpath.2020.07.013","volume":"190","author":"WC Chung","year":"2020","unstructured":"Chung, W. C., Zhou, X., Atfi, A. & Xu, K. PIK3CG is a potential therapeutic target in androgen receptor-indifferent metastatic prostate cancer. Am. J. Pathol. 190, 2194\u20132202 (2020).","journal-title":"Am. J. Pathol."},{"key":"2770_CR29","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/s41388-024-03085-2","volume":"43","author":"Y Zang","year":"2024","unstructured":"Zang, Y. et al. METTL3-mediated N(6)-methyladenosine modification of STAT5A promotes gastric cancer progression by regulating KLF4. Oncogene. 43, 2338\u20132354 (2024).","journal-title":"Oncogene."},{"key":"2770_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2006.04.003","volume":"3","author":"J Luo","year":"2006","unstructured":"Luo, J. et al. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab. 3, 355\u2013366 (2006).","journal-title":"Cell Metab."},{"key":"2770_CR31","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1126\/science.1150799","volume":"318","author":"CH Huang","year":"2007","unstructured":"Huang, C. H. et al. The structure of a human p110alpha\/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 318, 1744\u20131748 (2007).","journal-title":"Science."},{"key":"2770_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri1056","volume":"3","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317\u2013330 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"2770_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.tips.2023.06.002","volume":"44","author":"D Cirillo","year":"2023","unstructured":"Cirillo, D., Diceglie, M. & Nazar\u00e9, M. Isoform-selective targeting of PI3K: time to consider new opportunities? Trends Pharmacol. Sci. 44, 601\u2013621 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"2770_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fphar.2015.00169","volume":"6","author":"A Ghigo","year":"2015","unstructured":"Ghigo, A. & Li, M. Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. Front. Pharmacol. 6, 169 (2015).","journal-title":"Front. Pharmacol."},{"key":"2770_CR35","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ajpath.2012.01.030","volume":"180","author":"B Bartok","year":"2012","unstructured":"Bartok, B. et al. PI3 kinase \u03b4 is a key regulator of synoviocyte function in rheumatoid arthritis. Am. J. Pathol. 180, 1906\u20131916 (2012).","journal-title":"Am. J. Pathol."},{"key":"2770_CR36","doi-asserted-by":"publisher","first-page":"100359","DOI":"10.1016\/j.jhepr.2021.100359","volume":"3","author":"B Becattini","year":"2021","unstructured":"Becattini, B. et al. PI3K\u03b3 promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation. JHEP Rep. 3, 100359 (2021).","journal-title":"JHEP Rep."},{"key":"2770_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer, I. A. et al. A phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer. Clin. Cancer Res. 23, 26\u201334 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","volume":"617","author":"JS Bergholz","year":"2023","unstructured":"Bergholz, J. S. et al. PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours. Nature. 617, 139\u2013146 (2023).","journal-title":"Nature."},{"key":"2770_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas, C. L. et al. PI3K\u03b4 and primary immunodeficiencies. Nat. Rev. Immunol. 16, 702\u2013714 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2770_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/ajh.27569","volume":"100","author":"JE Bruno","year":"2025","unstructured":"Bruno, J. E. et al. Treatment of relapsed\/refractory CLL patients with PI3K\u03b4 inhibitor and anti-CD20 antibody rapidly decreases tumor burden but could induce resistance. Am. J. Hematol. 100, 523\u2013526 (2025).","journal-title":"Am. J. Hematol."},{"key":"2770_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","volume":"138","author":"M Li","year":"2018","unstructured":"Li, M. et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 138, 696\u2013711 (2018).","journal-title":"Circulation"},{"key":"2770_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan, S. M., Wymann, M. P. & Lucas, C. L. The role of PI3K\u03b3 in the immune system: new insights and translational implications. Nat. Rev. Immunol. 22, 687\u2013700 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2770_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer. 20, 74\u201388 (2020).","journal-title":"Nat. Rev. Cancer."},{"key":"2770_CR44","doi-asserted-by":"publisher","first-page":"112172","DOI":"10.1016\/j.celrep.2023.112172","volume":"42","author":"MK Rathinaswamy","year":"2023","unstructured":"Rathinaswamy, M. K. et al. Molecular basis for differential activation of p101 and p84 complexes of PI3K\u03b3 by Ras and GPCRs. Cell Rep. 42, 112172 (2023).","journal-title":"Cell Rep."},{"key":"2770_CR45","doi-asserted-by":"publisher","first-page":"17063","DOI":"10.1038\/sigtrans.2017.63","volume":"2","author":"AD Whale","year":"2017","unstructured":"Whale, A. D. et al. Functional characterization of a novel somatic oncogenic mutation of PIK3CB. Signal Transduct. Target Ther. 2, 17063 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"2770_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1097-2765(01)00191-5","volume":"7","author":"I Gaidarov","year":"2001","unstructured":"Gaidarov, I., Smith, M. E., Domin, J. & Keen, J. H. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell. 7, 443\u2013449 (2001).","journal-title":"Mol. Cell."},{"key":"2770_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2770_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/biom9030104","volume":"9","author":"JP Margaria","year":"2019","unstructured":"Margaria, J. P. et al. Class II PI3Ks at the intersection between signal transduction and membrane trafficking. Biomolecules. 9, 104 (2019).","journal-title":"Biomolecules."},{"key":"2770_CR49","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1080\/15548627.2015.1043076","volume":"11","author":"X Yu","year":"2015","unstructured":"Yu, X., Long, Y. C. & Shen, H. M. Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. Autophagy. 11, 1711\u20131728 (2015).","journal-title":"Autophagy."},{"key":"2770_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/acs.jmedchem.6b00963","volume":"60","author":"M Falasca","year":"2017","unstructured":"Falasca, M. et al. Class II phosphoinositide 3-kinases as novel drug targets. J. Med. Chem. 60, 47\u201365 (2017).","journal-title":"J. Med. Chem."},{"key":"2770_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adg1913","volume":"16","author":"P Kobialka","year":"2023","unstructured":"Kobialka, P. et al. PI3K-C2\u03b2 limits mTORC1 signaling and angiogenic growth. Sci. Signal. 16, eadg1913 (2023).","journal-title":"Sci. Signal."},{"key":"2770_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/gutjnl-2021-325117","volume":"72","author":"MC De Santis","year":"2023","unstructured":"De Santis, M. C. et al. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Gut. 72, 360\u2013371 (2023).","journal-title":"Gut."},{"key":"2770_CR53","doi-asserted-by":"publisher","first-page":"1114572","DOI":"10.3389\/fimmu.2023.1114572","volume":"14","author":"C Qin","year":"2023","unstructured":"Qin, C. et al. PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. Front. Immunol. 14, 1114572 (2023).","journal-title":"Front. Immunol."},{"key":"2770_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7535","volume":"6","author":"JK Mountford","year":"2015","unstructured":"Mountford, J. K. et al. The class II PI 3-kinase, PI3KC2\u03b1, links platelet internal membrane structure to shear-dependent adhesive function. Nat. Commun. 6, 6535 (2015).","journal-title":"Nat. Commun."},{"key":"2770_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.tcb.2019.01.001","volume":"29","author":"F Gulluni","year":"2019","unstructured":"Gulluni, F. et al. Class II PI3K functions in cell biology and disease. Trends Cell Biol. 29, 339\u2013359 (2019).","journal-title":"Trends Cell Biol."},{"key":"2770_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8400","volume":"6","author":"L Braccini","year":"2015","unstructured":"Braccini, L. et al. PI3K-C2\u03b3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat. Commun. 6, 7400 (2015).","journal-title":"Nat. Commun."},{"key":"2770_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0450-3","volume":"17","author":"N Hinz","year":"2019","unstructured":"Hinz, N. & J\u00fccker, M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun. Signal. 17, 154 (2019).","journal-title":"Cell Commun. Signal."},{"key":"2770_CR58","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","volume":"28","author":"M Shariati","year":"2019","unstructured":"Shariati, M. & Meric-Bernstam, F. Targeting AKT for cancer therapy. Expert Opin. Investig. Drugs 28, 977\u2013988 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2770_CR59","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell. 169, 381\u2013405 (2017).","journal-title":"Cell."},{"key":"2770_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44772-8","volume":"15","author":"T Chen","year":"2024","unstructured":"Chen, T. et al. AKT1 phosphorylation of cytoplasmic ME2 induces a metabolic switch to glycolysis for tumorigenesis. Nat. Commun. 15, 686 (2024).","journal-title":"Nat. Commun."},{"key":"2770_CR61","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.molcel.2010.02.031","volume":"38","author":"YR Chin","year":"2010","unstructured":"Chin, Y. R. & Toker, A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol. Cell. 38, 333\u2013344 (2010).","journal-title":"Mol. Cell."},{"key":"2770_CR62","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1083\/jcb.200505087","volume":"171","author":"HY Irie","year":"2005","unstructured":"Irie, H. Y. et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171, 1023\u20131034 (2005).","journal-title":"J. Cell Biol."},{"key":"2770_CR63","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/bjc.2012.295","volume":"107","author":"A Goc","year":"2012","unstructured":"Goc, A., Liu, J., Byzova, T. V. & Somanath, P. R. Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin \u03b2\u2083 affinity modulation. Br. J. Cancer. 107, 713\u2013723 (2012).","journal-title":"Br. J. Cancer."},{"key":"2770_CR64","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1073\/pnas.1414573112","volume":"112","author":"KM Turner","year":"2015","unstructured":"Turner, K. M. et al. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc. Natl. Acad. Sci. USA 112, 3421\u20133426 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR65","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.7150\/ijbs.83774","volume":"20","author":"W Du","year":"2024","unstructured":"Du, W. et al. UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT. Int. J. Biol. Sci. 20, 1389\u20131409 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR66","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","volume":"7","author":"DR Alessi","year":"1997","unstructured":"Alessi, D. R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7, 261\u2013269 (1997).","journal-title":"Curr. Biol."},{"key":"2770_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba5672","volume":"6","author":"K Paunovska","year":"2020","unstructured":"Paunovska, K. et al. Increased PIP3 activity blocks nanoparticle mRNA delivery. Sci. Adv. 6, eaba5672 (2020).","journal-title":"Sci. Adv."},{"key":"2770_CR68","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 307, 1098\u20131101 (2005).","journal-title":"Science."},{"key":"2770_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu, G. Y. & Sabatini, D. M. mTOR at the nexus of nutrition, growth, ageing and disease. Nat. Rev. Mol. Cell Biol. 21, 183\u2013203 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2770_CR70","doi-asserted-by":"publisher","first-page":"39450","DOI":"10.1074\/jbc.M111.265330","volume":"286","author":"N Case","year":"2011","unstructured":"Case, N. et al. Mechanical regulation of glycogen synthase kinase 3\u03b2 (GSK3\u03b2) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein. J. Biol. Chem. 286, 39450\u201339456 (2011).","journal-title":"J. Biol. Chem."},{"key":"2770_CR71","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","volume":"7","author":"S Frame","year":"2001","unstructured":"Frame, S., Cohen, P. & Biondi, R. M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell. 7, 1321\u20131327 (2001).","journal-title":"Mol. Cell."},{"key":"2770_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","volume":"11","author":"Y Xu","year":"2022","unstructured":"Xu, Y. & Ye, H. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Exp. Hematol. Oncol. 11, 31 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"2770_CR73","doi-asserted-by":"publisher","first-page":"115299","DOI":"10.1016\/j.biopha.2023.115299","volume":"166","author":"M Alipour","year":"2023","unstructured":"Alipour, M. et al. DNAi-peptide nanohybrid smart particles target BCL-2 oncogene and induce apoptosis in breast cancer cells. Biomed. Pharmacother. 166, 115299 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2770_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01207-z","volume":"21","author":"A Oh","year":"2023","unstructured":"Oh, A. et al. NF-\u03baB signaling in neoplastic transition from epithelial to mesenchymal phenotype. Cell Commun. Signal. 21, 291 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2770_CR75","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.tips.2022.09.010","volume":"43","author":"A Orea-Soufi","year":"2022","unstructured":"Orea-Soufi, A. et al. FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol. Sci. 43, 1070\u20131084 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"2770_CR76","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-020-0088-2","volume":"20","author":"G Calissi","year":"2021","unstructured":"Calissi, G., Lam, E. W. & Link, W. Therapeutic strategies targeting FOXO transcription factors. Nat. Rev. Drug Discov. 20, 21\u201338 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2770_CR77","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10555-020-09883-w","volume":"39","author":"Y Jiramongkol","year":"2020","unstructured":"Jiramongkol, Y. & Lam, E. W. FOXO transcription factor family in cancer and metastasis. Cancer Metastasis Rev. 39, 681\u2013709 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"2770_CR78","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcancer.2017.11.017","volume":"50","author":"M Hornsveld","year":"2018","unstructured":"Hornsveld, M., Dansen, T. B., Derksen, P. W. & Burgering, B. M. T. Re-evaluating the role of FOXOs in cancer. Semin. Cancer Biol. 50, 90\u2013100 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR79","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/bloodadvances.2019001393","volume":"4","author":"TA Bloedjes","year":"2020","unstructured":"Bloedjes, T. A. et al. AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. Blood Adv. 4, 4151\u20134164 (2020).","journal-title":"Blood Adv."},{"key":"2770_CR80","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","volume":"8","author":"N Hay","year":"2005","unstructured":"Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8, 179\u2013183 (2005).","journal-title":"Cancer Cell."},{"key":"2770_CR81","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1146\/annurev-biochem-082411-113907","volume":"83","author":"CA Worby","year":"2014","unstructured":"Worby, C. A. & Dixon, J. E. PTEN. Annu. Rev. Biochem. 83, 641\u2013669 (2014).","journal-title":"Annu. Rev. Biochem."},{"key":"2770_CR82","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.tcb.2013.03.003","volume":"23","author":"A Naguib","year":"2013","unstructured":"Naguib, A. & Trotman, L. C. PTEN plasticity: how the taming of a lethal gene can go too far. Trends Cell Biol. 23, 374\u2013379 (2013).","journal-title":"Trends Cell Biol."},{"key":"2770_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06856-0","volume":"9","author":"S Matsuoka","year":"2018","unstructured":"Matsuoka, S. & Ueda, M. Mutual inhibition between PTEN and PIP3 generates bistability for polarity in motile cells. Nat. Commun. 9, 4481 (2018).","journal-title":"Nat. Commun."},{"key":"2770_CR84","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tem.2012.11.002","volume":"24","author":"A Ortega-Molina","year":"2013","unstructured":"Ortega-Molina, A. & Serrano, M. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metab. 24, 184\u2013189 (2013).","journal-title":"Trends Endocrinol. Metab."},{"key":"2770_CR85","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/cmi.2017.30","volume":"14","author":"L Chen","year":"2017","unstructured":"Chen, L. & Guo, D. The functions of tumor suppressor PTEN in innate and adaptive immunity. Cell. Mol. Immunol. 14, 581\u2013589 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"2770_CR86","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","volume":"59","author":"V \u00c1lvarez-Garcia","year":"2019","unstructured":"\u00c1lvarez-Garcia, V., Tawil, Y., Wise, H. M. & Leslie, N. R. Mechanisms of PTEN loss in cancer: it\u2019s all about diversity. Semin. Cancer Biol. 59, 66\u201379 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2021.12.003","volume":"527","author":"C Chai","year":"2022","unstructured":"Chai, C. et al. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett. 527, 41\u201348 (2022).","journal-title":"Cancer Lett."},{"key":"2770_CR88","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.jid.2023.01.034","volume":"143","author":"s Chagani","year":"2023","unstructured":"Chagani, s. et al. multiplatform Analysis of Intratumoral PTEN heterogeneity in melanoma. J. Invest. Dermatol. 143, 1779\u20131787 (2023).","journal-title":"J. Invest. Dermatol."},{"key":"2770_CR89","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1001\/jama.2010.1863","volume":"304","author":"D Jelovac","year":"2010","unstructured":"Jelovac, D. & Park, B. H. PTEN promoter silencing and Cowden syndrome: the role of epigenetic regulation of KILLIN. JAMA 304, 2744\u20132745 (2010).","journal-title":"JAMA"},{"key":"2770_CR90","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41422-020-00443-z","volume":"31","author":"P Xie","year":"2021","unstructured":"Xie, P. et al. Neddylation of PTEN regulates its nuclear import and promotes tumor development. Cell Res. 31, 291\u2013311 (2021).","journal-title":"Cell Res."},{"key":"2770_CR91","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed, A., Kim, E. & Jacinto, E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol. Rev. 101, 1371\u20131426 (2021).","journal-title":"Physiol. Rev."},{"key":"2770_CR92","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1080\/15548627.2020.1713640","volume":"16","author":"M Bernard","year":"2020","unstructured":"Bernard, M. et al. Autophagy drives fibroblast senescence through MTORC2 regulation. Autophagy. 16, 2004\u20132016 (2020).","journal-title":"Autophagy."},{"key":"2770_CR93","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2017.11.011","volume":"32","author":"Y Guri","year":"2017","unstructured":"Guri, Y. et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell. 32, 807\u2013823 (2017).","journal-title":"Cancer Cell."},{"key":"2770_CR94","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu, L., Wei, J. & Liu, P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin. Cancer Biol. 85, 69\u201394 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR95","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N. Engl. J. Med. 391, 710\u2013721 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2770_CR96","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamaoncol.2022.7966","volume":"9","author":"S Banerjee","year":"2023","unstructured":"Banerjee, S. et al. Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncol. 9, 675\u2013682 (2023).","journal-title":"JAMA Oncol."},{"key":"2770_CR97","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/IM9.0000000000000119","volume":"5","author":"F Bian","year":"2023","unstructured":"Bian, F., Yan, D., Wu, X. & Yang, C. A Biological perspective of tlr8 signaling in host defense and inflammation. Infect. Microbes Dis. 5, 44\u201355 (2023).","journal-title":"Infect. Microbes Dis."},{"key":"2770_CR98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 62, 50\u201360 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"2770_CR99","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.biopha.2017.06.061","volume":"93","author":"Q Xiao","year":"2017","unstructured":"Xiao, Q. et al. The many postures of noncanonical Wnt signaling in development and diseases. Biomed. Pharmacother. 93, 359\u2013369 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"2770_CR100","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2174\/1874467216666221017122105","volume":"16","author":"M Talebi","year":"2023","unstructured":"Talebi, M. et al. Mechanistic features and therapeutic implications related to the miRNAs and Wnt signaling regulatory in breast cancer. Curr. Mol. Pharmacol. 16, 530\u2013541 (2023).","journal-title":"Curr. Mol. Pharmacol."},{"key":"2770_CR101","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7150\/ijbs.23756","volume":"14","author":"G Li","year":"2018","unstructured":"Li, G. et al. Frizzled7 promotes epithelial-to-mesenchymal transition and stemness via activating canonical Wnt\/\u03b2-catenin pathway in gastric cancer. Int. J. Biol. Sci. 14, 280\u2013293 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR102","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrm3470","volume":"13","author":"C Niehrs","year":"2012","unstructured":"Niehrs, C. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 13, 767\u2013779 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2770_CR103","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.it.2018.08.006","volume":"39","author":"WJ Chae","year":"2018","unstructured":"Chae, W. J. & Bothwell, A. L. M. Canonical and non-canonical Wnt signaling in immune cells. Trends Immunol. 39, 830\u2013847 (2018).","journal-title":"Trends Immunol."},{"key":"2770_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04963-x","volume":"13","author":"K Chen","year":"2022","unstructured":"Chen, K. et al. The role of the PI3K\/AKT signalling pathway in the corneal epithelium: recent updates. Cell Death Dis. 13, 513 (2022).","journal-title":"Cell Death Dis."},{"key":"2770_CR105","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/antiox13020199","volume":"13","author":"VH Trinh","year":"2024","unstructured":"Trinh, V. H. et al. Redox regulation of pten by reactive oxygen species: its role in physiological processes. Antioxidants 13, 199 (2024).","journal-title":"Antioxidants"},{"key":"2770_CR106","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/svn-2022-001498","volume":"8","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. MALAT1 promotes platelet activity and thrombus formation through PI3k\/Akt\/GSK-3\u03b2 signalling pathway. Stroke Vasc. Neurol. 8, 181\u2013192 (2023).","journal-title":"Stroke Vasc. Neurol."},{"key":"2770_CR107","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.gendis.2020.05.002","volume":"9","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. PTEN and AKT\/GSK-3\u03b2\/CRMP-2 signaling pathway are involved in neuronal apoptosis and axonal injury in early brain injury after SAH in rats. Genes Dis. 9, 252\u2013267 (2022).","journal-title":"Genes Dis."},{"key":"2770_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2018.01.018","volume":"50","author":"J Ma","year":"2018","unstructured":"Ma, J., Matkar, S., He, X. & Hua, X. FOXO family in regulating cancer and metabolism. Semin. Cancer Biol. 50, 32\u201341 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR109","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s11427-016-9050-6","volume":"61","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells. Sci. China Life Sci. 61, 550\u2013558 (2018).","journal-title":"Sci. China Life Sci."},{"key":"2770_CR110","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cellsig.2015.01.001","volume":"27","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. FOXO3a modulates WNT\/\u03b2-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell. Signal. 27, 510\u2013518 (2015).","journal-title":"Cell. Signal."},{"key":"2770_CR111","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.7150\/ijbs.61350","volume":"17","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. TNF-\u03b1 augments CXCL10\/CXCR3 axis activity to induce epithelial-mesenchymal transition in colon cancer cell. Int. J. Biol. Sci. 17, 2683\u20132702 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR112","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1042\/BST20220866","volume":"51","author":"SJ Rodgers","year":"2023","unstructured":"Rodgers, S. J., Mitchell, C. A. & Ooms, L. M. The mechanisms of class 1A PI3K and Wnt\/\u03b2-catenin coupled signaling in breast cancer. Biochem. Soc. Trans. 51, 1459\u20131472 (2023).","journal-title":"Biochem. Soc. Trans."},{"key":"2770_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23241-6","volume":"12","author":"SJ Rodgers","year":"2021","unstructured":"Rodgers, S. J. et al. INPP4B promotes PI3K\u03b1-dependent late endosome formation and Wnt\/\u03b2-catenin signaling in breast cancer. Nat. Commun. 12, 3140 (2021).","journal-title":"Nat. Commun."},{"key":"2770_CR114","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.molcel.2014.09.023","volume":"56","author":"JA Gasser","year":"2014","unstructured":"Gasser, J. A. et al. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol. Cell. 56, 595\u2013607 (2014).","journal-title":"Mol. Cell."},{"key":"2770_CR115","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molmed.2016.03.002","volume":"22","author":"G Cildir","year":"2016","unstructured":"Cildir, G., Low, K. C. & Tergaonkar, V. Noncanonical NF-\u03baB signaling in health and disease. Trends Mol. Med. 22, 414\u2013429 (2016).","journal-title":"Trends Mol. Med."},{"key":"2770_CR116","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q., Lenardo, M. J. & Baltimore, D. 30 Years of NF-\u03baB: a blossoming of relevance to human pathobiology. Cell. 168, 37\u201357 (2017).","journal-title":"Cell."},{"key":"2770_CR117","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri910","volume":"2","author":"Q Li","year":"2002","unstructured":"Li, Q. & Verma, I. M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2, 725\u2013734 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"2770_CR118","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semcancer.2021.07.015","volume":"85","author":"S Ahmad","year":"2022","unstructured":"Ahmad, S. et al. Long non-coding RNAs regulated NF-\u03baB signaling in cancer metastasis: micromanaging by not so small non-coding RNAs. Semin. Cancer Biol. 85, 155\u2013163 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR119","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu, S. & Karin, M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693\u2013733 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"2770_CR120","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat. Immunol."},{"key":"2770_CR121","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cytogfr.2008.01.006","volume":"19","author":"JA Schmid","year":"2008","unstructured":"Schmid, J. A. & Birbach, A. IkappaB kinase beta (IKKbeta\/IKK2\/IKBKB)\u2013a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor. Rev. 19, 157\u2013165 (2008).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"2770_CR122","doi-asserted-by":"publisher","first-page":"a000158","DOI":"10.1101\/cshperspect.a000158","volume":"2","author":"A Isra\u00ebl","year":"2010","unstructured":"Isra\u00ebl, A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2, a000158 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2770_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15075-5","volume":"11","author":"JI Jun","year":"2020","unstructured":"Jun, J. I. & Lau, L. F. CCN1 is an opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling. Nat. Commun. 11, 1242 (2020).","journal-title":"Nat. Commun."},{"key":"2770_CR124","doi-asserted-by":"publisher","first-page":"810671","DOI":"10.3389\/fimmu.2022.810671","volume":"13","author":"R Jiang","year":"2022","unstructured":"Jiang, R. et al. CCN1 promotes inflammation by inducing IL-6 production via \u03b16\u03b21\/PI3K\/Akt\/NF-\u03baB pathway in autoimmune hepatitis. Front. Immunol. 13, 810671 (2022).","journal-title":"Front. Immunol."},{"key":"2770_CR125","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13046-022-02531-x","volume":"41","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-\u03baBp65\/HK2 signalling. J. Exp. Clin. Cancer Res. 41, 329 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR126","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cels.2022.10.003","volume":"13","author":"AF Peterson","year":"2022","unstructured":"Peterson, A. F. et al. Systematic analysis of the MAPK signaling network reveals MAP3K-driven control of cell fate. Cell Syst. 13, 885\u2013894 (2022).","journal-title":"Cell Syst."},{"key":"2770_CR127","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S1470-2045(05)70168-6","volume":"6","author":"JY Fang","year":"2005","unstructured":"Fang, J. Y. & Richardson, B. C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6, 322\u2013327 (2005).","journal-title":"Lancet Oncol."},{"key":"2770_CR128","doi-asserted-by":"publisher","first-page":"e13436","DOI":"10.1111\/imr.13436","volume":"329","author":"A Vervaeke","year":"2025","unstructured":"Vervaeke, A. & Lamkanfi, M. MAP Kinase Signaling at the crossroads of inflammasome activation. Immunol. Rev. 329, e13436 (2025).","journal-title":"Immunol. Rev."},{"key":"2770_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04474-1","volume":"13","author":"H Huang","year":"2021","unstructured":"Huang, H. et al. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis. 13, 13 (2021).","journal-title":"Cell Death Dis."},{"key":"2770_CR130","doi-asserted-by":"publisher","first-page":"188736","DOI":"10.1016\/j.bbcan.2022.188736","volume":"1877","author":"HB Park","year":"2022","unstructured":"Park, H. B. & Baek, K. H. E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. Biochim. Biophys. Acta Rev. Cancer. 1877, 188736 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"key":"2770_CR131","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/ijms21031102","volume":"21","author":"S Lee","year":"2020","unstructured":"Lee, S., Rauch, J. & Kolch, W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int. J. Mol. Sci. 21, 1102 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR132","doi-asserted-by":"publisher","first-page":"110853","DOI":"10.1016\/j.biopha.2020.110853","volume":"132","author":"A Safa","year":"2020","unstructured":"Safa, A. et al. MicroRNAs as regulators of ERK\/MAPK pathway: a comprehensive review. Biomed. Pharmacother. 132, 110853 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2770_CR133","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell. 170, 17\u201333 (2017).","journal-title":"Cell."},{"key":"2770_CR134","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan, J., Dong, X., Yap, J. & Hu, J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J. Hematol. Oncol. 13, 113 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2770_CR135","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0092-8674(00)00196-3","volume":"103","author":"ME Pacold","year":"2000","unstructured":"Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 103, 931\u2013943 (2000).","journal-title":"Cell."},{"key":"2770_CR136","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/pharmaceutics14030590","volume":"14","author":"S Candido","year":"2022","unstructured":"Candido, S. et al. The PIK3CA H1047R mutation confers resistance to BRAF and MEK inhibitors in A375 melanoma cells through the cross-activation of MAPK and PI3K-Akt pathways. Pharmaceutics. 14, 590 (2022).","journal-title":"Pharmaceutics."},{"key":"2770_CR137","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","volume":"37","author":"M Drosten","year":"2020","unstructured":"Drosten, M. & Barbacid, M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 37, 543\u2013550 (2020).","journal-title":"Cancer Cell."},{"key":"2770_CR138","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fendo.2018.00338","volume":"9","author":"CY Chen","year":"2018","unstructured":"Chen, C. Y., Chen, J., He, L. & Stiles, B. L. PTEN: tumor suppressor and metabolic regulator. Front. Endocrinol. 9, 338 (2018).","journal-title":"Front. Endocrinol."},{"key":"2770_CR139","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/neuonc\/not084","volume":"15","author":"M Vitucci","year":"2013","unstructured":"Vitucci, M. et al. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro Oncol. 15, 1317\u20131329 (2013).","journal-title":"Neuro Oncol."},{"key":"2770_CR140","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s12276-023-01062-5","volume":"55","author":"X Ren","year":"2023","unstructured":"Ren, X. et al. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK\/ERK and PI3K\/AKT pathways. Exp. Mol. Med. 55, 1757\u20131769 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2770_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01929-1","volume":"23","author":"D Liang","year":"2024","unstructured":"Liang, D. et al. JAK\/STAT in leukemia: a clinical update. Mol. Cancer. 23, 25 (2024).","journal-title":"Mol. Cancer."},{"key":"2770_CR142","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0092-8674(00)81288-X","volume":"84","author":"MA Meraz","year":"1996","unstructured":"Meraz, M. A. et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 84, 431\u2013442 (1996).","journal-title":"Cell."},{"key":"2770_CR143","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","volume":"39","author":"F Perner","year":"2025","unstructured":"Perner, F., Pahl, H. L., Zeiser, R. & Heidel, F. H. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia. 39, 1011\u20131030 (2025).","journal-title":"Leukemia."},{"key":"2770_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253","volume":"5","author":"K Yamaoka","year":"2004","unstructured":"Yamaoka, K. et al. The Janus kinases (Jaks). Genome Biol. 5, 253 (2004).","journal-title":"Genome Biol."},{"key":"2770_CR145","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1126\/science.abn8933","volume":"376","author":"CR Glassman","year":"2022","unstructured":"Glassman, C. R. et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science. 376, 163\u2013169 (2022).","journal-title":"Science."},{"key":"2770_CR146","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2022.08.003","volume":"86","author":"GL Wong","year":"2022","unstructured":"Wong, G. L., Manore, S. G., Doheny, D. L. & Lo, H. W. STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges. Semin. Cancer Biol. 86, 84\u2013106 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR147","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1158\/0008-5472.CAN-22-3407","volume":"83","author":"Z Sun","year":"2023","unstructured":"Sun, Z. et al. AKT blocks SIK1-mediated repression of STAT3 to promote breast tumorigenesis. Cancer Res. 83, 1264\u20131279 (2023).","journal-title":"Cancer Res."},{"key":"2770_CR148","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mce.2017.04.025","volume":"451","author":"PD R\u00e4dler","year":"2017","unstructured":"R\u00e4dler, P. D., Wehde, B. L. & Wagner, K. U. Crosstalk between STAT5 activation and PI3K\/AKT functions in normal and transformed mammary epithelial cells. Mol. Cell. Endocrinol. 451, 31\u201339 (2017).","journal-title":"Mol. Cell. Endocrinol."},{"key":"2770_CR149","doi-asserted-by":"publisher","first-page":"203661","DOI":"10.1016\/j.cdev.2021.203661","volume":"165","author":"J Wang","year":"2021","unstructured":"Wang, J., Feng, Q., Liang, D. & Shi, J. MiRNA-26a inhibits myocardial infarction-induced apoptosis by targeting PTEN via JAK\/STAT pathways. Cells Dev. 165, 203661 (2021).","journal-title":"Cells Dev."},{"key":"2770_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00529-y","volume":"13","author":"W Peng","year":"2024","unstructured":"Peng, W. et al. Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth. Oncogenesis. 13, 29 (2024).","journal-title":"Oncogenesis."},{"key":"2770_CR151","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9, J. TGFbeta in cancer. Cell. 134, 215\u2013230 (2008).","journal-title":"Cell."},{"key":"2770_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng, D. et al. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol. Cancer. 21, 104 (2022).","journal-title":"Mol. Cancer."},{"key":"2770_CR153","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429315125240919033502","volume":"17","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Doxazosin attenuates development of testosterone propionate-induced prostate growth by regulating TGF-\u03b2\/Smad signaling pathway, prostate-specific antigen expression and reversing epithelial-mesenchymal transition in mice and stroma cells. Curr. Mol. Pharmacol. 17, e18761429315125 (2025).","journal-title":"Curr. Mol. Pharmacol."},{"key":"2770_CR154","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nrc3603","volume":"13","author":"M Pickup","year":"2013","unstructured":"Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGF\u03b2 in the tumour microenvironment. Nat. Rev. Cancer. 13, 788\u2013799 (2013).","journal-title":"Nat. Rev. Cancer."},{"key":"2770_CR155","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng1001-117","volume":"29","author":"R Derynck","year":"2001","unstructured":"Derynck, R., Akhurst, R. J. & Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117\u2013129 (2001).","journal-title":"Nat. Genet."},{"key":"2770_CR156","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","volume":"32","author":"MA Travis","year":"2014","unstructured":"Travis, M. A. & Sheppard, D. TGF-\u03b2 activation and function in immunity. Annu. Rev. Immunol. 32, 51\u201382 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"2770_CR157","first-page":"E4168","volume":"114","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Atypical interactions of integrin \u03b1(V)\u03b2(8) with pro-TGF-\u03b21. Proc. Natl. Acad. Sci. USA 114, E4168\u2013E4174 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR158","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.intimp.2020.107101","volume":"89","author":"H Zhao","year":"2020","unstructured":"Zhao, H., Wei, J. & Sun, J. Roles of TGF-\u03b2 signaling pathway in tumor microenvirionment and cancer therapy. Int. Immunopharmacol. 89, 107101 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2770_CR159","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9, J. & Sheppard, D. TGF-\u03b2 signaling in health and disease. Cell. 186, 4007\u20134037 (2023).","journal-title":"Cell."},{"key":"2770_CR160","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 50, 924\u2013940 (2019).","journal-title":"Immunity."},{"key":"2770_CR161","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0270","volume":"2","author":"G Xue","year":"2012","unstructured":"Xue, G. et al. Akt\/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K\/Akt and TGF-\u03b2 signaling axes. Cancer Discov. 2, 248\u2013259 (2012).","journal-title":"Cancer Discov."},{"key":"2770_CR162","doi-asserted-by":"publisher","first-page":"231","DOI":"10.7150\/ijbs.86317","volume":"20","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. Hypoxia-driven TNS4 fosters HNSCC tumorigenesis by stabilizing integrin \u03b15\u03b21 complex and triggering FAK-mediated Akt and TGF\u03b2 signaling pathways. Int. J. Biol. Sci. 20, 231\u2013248 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06282-z","volume":"23","author":"J Sun","year":"2025","unstructured":"Sun, J. et al. Notch signaling in the tumor immune microenvironment of colorectal cancer: mechanisms and therapeutic opportunities. J. Transl. Med. 23, 315 (2025).","journal-title":"J. Transl. Med."},{"key":"2770_CR164","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","volume":"137","author":"R Kopan","year":"2009","unstructured":"Kopan, R. & Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 137, 216\u2013233 (2009).","journal-title":"Cell."},{"key":"2770_CR165","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-biophys-101920-082204","volume":"50","author":"D Sprinzak","year":"2021","unstructured":"Sprinzak, D. & Blacklow, S. C. Biophysics of Notch signaling. Annu. Rev. Biophys. 50, 157\u2013189 (2021).","journal-title":"Annu. Rev. Biophys."},{"key":"2770_CR166","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.tem.2021.08.002","volume":"32","author":"GE Moldovan","year":"2021","unstructured":"Moldovan, G. E., Miele, L. & Fazleabas, A. T. Notch signaling in reproduction. Trends Endocrinol. Metab. 32, 1044\u20131057 (2021).","journal-title":"Trends Endocrinol. Metab."},{"key":"2770_CR167","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1172\/JCI37964","volume":"120","author":"J Ma","year":"2010","unstructured":"Ma, J. et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3\/p63\/Jagged\/Notch cascade. J. Clin. Invest. 120, 103\u2013114 (2010).","journal-title":"J. Clin. Invest."},{"key":"2770_CR168","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/glia.22669","volume":"62","author":"F Gagliardi","year":"2014","unstructured":"Gagliardi, F. et al. The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia. 62, 1015\u20131023 (2014).","journal-title":"Glia."},{"key":"2770_CR169","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13046-019-1319-4","volume":"38","author":"L Yi","year":"2019","unstructured":"Yi, L. et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12\/CXCR4. J. Exp. Clin. Cancer Res. 38, 339 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR170","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2020005381","volume":"137","author":"T Khanam","year":"2021","unstructured":"Khanam, T. et al. Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. 137, 2347\u20132359 (2021).","journal-title":"Blood."},{"key":"2770_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07241-0","volume":"15","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. NOTCH3 promotes malignant progression of bladder cancer by directly regulating SPP1 and activating PI3K\/AKT pathway. Cell Death Dis. 15, 840 (2024).","journal-title":"Cell Death Dis."},{"key":"2770_CR172","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1101\/gad.938601","volume":"15","author":"PW Ingham","year":"2001","unstructured":"Ingham, P. W. & McMahon, A. P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059\u20133087 (2001).","journal-title":"Genes Dev."},{"key":"2770_CR173","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1242\/dev.083691","volume":"141","author":"R Petrova","year":"2014","unstructured":"Petrova, R. & Joyner, A. L. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 141, 3445\u20133457 (2014).","journal-title":"Development."},{"key":"2770_CR174","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrg2984","volume":"12","author":"PW Ingham","year":"2011","unstructured":"Ingham, P. W., Nakano, Y. & Seger, C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat. Rev. Genet. 12, 393\u2013406 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"2770_CR175","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq1790","volume":"11","author":"Y Han","year":"2025","unstructured":"Han, Y., Zhou, M., Wang, B. & Jiang, J. Morphogen-induced kinase condensates transduce Hh signal by allosterically activating Gli. Sci. Adv. 11, eadq1790 (2025).","journal-title":"Sci. Adv."},{"key":"2770_CR176","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-018-0308-7","volume":"560","author":"X Qi","year":"2018","unstructured":"Qi, X. et al. Structures of human Patched and its complex with native palmitoylated sonic hedgehog. Nature. 560, 128\u2013132 (2018).","journal-title":"Nature."},{"key":"2770_CR177","doi-asserted-by":"publisher","DOI":"10.1126\/science.aas8935","volume":"361","author":"X Gong","year":"2018","unstructured":"Gong, X. et al. Structural basis for the recognition of Sonic Hedgehog by human Patched1. Science. 361, eaas8935 (2018).","journal-title":"Science."},{"key":"2770_CR178","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrm3598","volume":"14","author":"J Briscoe","year":"2013","unstructured":"Briscoe, J. & Th\u00e9rond, P. P. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 14, 416\u2013429 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2770_CR179","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang, J. Hedgehog signaling mechanism and role in cancer. Semin. Cancer Biol. 85, 107\u2013122 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03504-2","volume":"12","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia. Cell Death Dis. 12, 231 (2021).","journal-title":"Cell Death Dis."},{"key":"2770_CR181","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1158\/0008-5472.CAN-11-1338","volume":"71","author":"YA Yoo","year":"2011","unstructured":"Yoo, Y. A. et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 71, 7061\u20137070 (2011).","journal-title":"Cancer Res."},{"key":"2770_CR182","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1073\/pnas.0701158104","volume":"104","author":"JP Morton","year":"2007","unstructured":"Morton, J. P. et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc. Natl. Acad. Sci. USA 104, 5103\u20135108 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu, R. et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 11, 797 (2020).","journal-title":"Cell Death Dis."},{"key":"2770_CR184","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000339016","volume":"1","author":"DY Kim","year":"2012","unstructured":"Kim, D. Y. & Han, K. H. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 1, 2\u201314 (2012).","journal-title":"Liver Cancer."},{"key":"2770_CR185","doi-asserted-by":"publisher","first-page":"2156255","DOI":"10.1080\/19490976.2022.2156255","volume":"15","author":"X Chai","year":"2023","unstructured":"Chai, X. et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes. 15, 2156255 (2023).","journal-title":"Gut Microbes."},{"key":"2770_CR186","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000343828","volume":"1","author":"S Lin","year":"2012","unstructured":"Lin, S., Hoffmann, K. & Schemmer, P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer. 1, 144\u2013158 (2012).","journal-title":"Liver Cancer."},{"key":"2770_CR187","doi-asserted-by":"publisher","first-page":"106553","DOI":"10.1016\/j.phrs.2022.106553","volume":"187","author":"MDA Paskeh","year":"2023","unstructured":"Paskeh, M. D. A. et al. Biological impact and therapeutic perspective of targeting PI3K\/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Pharmacol. Res. 187, 106553 (2023).","journal-title":"Pharmacol. Res."},{"key":"2770_CR188","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 169, 1327\u20131341.e1323 (2017).","journal-title":"Cell."},{"key":"2770_CR189","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/1878-0261.13135","volume":"16","author":"A Scheiter","year":"2022","unstructured":"Scheiter, A. et al. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. Mol. Oncol. 16, 1091\u20131118 (2022).","journal-title":"Mol. Oncol."},{"key":"2770_CR190","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/liv.13055","volume":"36","author":"C Wang","year":"2016","unstructured":"Wang, C. et al. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2\/mTORC1 cascade. Liver Int. 36, 1176\u20131186 (2016).","journal-title":"Liver Int."},{"key":"2770_CR191","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.tcb.2024.10.008","volume":"35","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. & Jiang, L. Targeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance. Trends Cell Biol. 35, 667\u2013677 (2024).","journal-title":"Trends Cell Biol."},{"key":"2770_CR192","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jhep.2018.02.014","volume":"69","author":"JJ Liu","year":"2018","unstructured":"Liu, J. J. et al. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic \u03b2-Catenin, PIK3CA and MET. J. Hepatol. 69, 79\u201388 (2018).","journal-title":"J. Hepatol."},{"key":"2770_CR193","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/hep.25576","volume":"55","author":"Y Fang","year":"2012","unstructured":"Fang, Y. et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase\/Akt pathway in hepatocellular carcinoma. Hepatology. 55, 1852\u20131862 (2012).","journal-title":"Hepatology."},{"key":"2770_CR194","doi-asserted-by":"publisher","first-page":"101690","DOI":"10.1016\/j.isci.2020.101690","volume":"23","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. The mutational and transcriptional landscapes of hepatocarcinogenesis in a rat model. iScience. 23, 101690 (2020).","journal-title":"iScience."},{"key":"2770_CR195","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/ijc.26319","volume":"130","author":"F Dituri","year":"2012","unstructured":"Dituri, F. et al. PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int. J. Cancer. 130, 2505\u20132513 (2012).","journal-title":"Int. J. Cancer."},{"key":"2770_CR196","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.bbadis.2017.04.014","volume":"1863","author":"X Zhao","year":"2017","unstructured":"Zhao, X., Liu, Y. & Yu, S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 1805\u20131816 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2770_CR197","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ajpath.2019.11.010","volume":"190","author":"SQ Li","year":"2020","unstructured":"Li, S. Q. et al. Long intergenic nonprotein coding rna 0152 promotes hepatocellular carcinoma progression by regulating phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin signaling pathway through miR-139\/PIK3CA. Am. J. Pathol. 190, 1095\u20131107 (2020).","journal-title":"Am. J. Pathol."},{"key":"2770_CR198","doi-asserted-by":"publisher","first-page":"2483780","DOI":"10.1080\/19490976.2025.2483780","volume":"17","author":"B Thulasinathan","year":"2025","unstructured":"Thulasinathan, B. et al. The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention. Gut Microbes. 17, 2483780 (2025).","journal-title":"Gut Microbes."},{"key":"2770_CR199","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10654-019-00549-8","volume":"35","author":"M Schulpen","year":"2020","unstructured":"Schulpen, M. & van den Brandt, P. A. Mediterranean diet adherence and risk of colorectal cancer: the prospective Netherlands Cohort Study. Eur. J. Epidemiol. 35, 25\u201335 (2020).","journal-title":"Eur. J. Epidemiol."},{"key":"2770_CR200","first-page":"145","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA. Cancer J. Clin. 70, 145\u2013164 (2020).","journal-title":"CA. Cancer J. Clin."},{"key":"2770_CR201","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.mayocp.2013.09.006","volume":"89","author":"DJ Ahnen","year":"2014","unstructured":"Ahnen, D. J. et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin. Proc. 89, 216\u2013224 (2014).","journal-title":"Mayo Clin. Proc."},{"key":"2770_CR202","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani, C. et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int. J. Mol. Sci. 22, 10260 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02180-y","volume":"23","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. THBS2\u2009+\u2009cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer. Mol. Cancer. 23, 282 (2024).","journal-title":"Mol. Cancer."},{"key":"2770_CR204","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).","journal-title":"Science"},{"key":"2770_CR205","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","volume":"7","author":"Y Samuels","year":"2005","unstructured":"Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561\u2013573 (2005).","journal-title":"Cancer Cell"},{"key":"2770_CR206","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdn541","volume":"20","author":"F Perrone","year":"2009","unstructured":"Perrone, F. et al. PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84\u201390 (2009).","journal-title":"Ann. Oncol."},{"key":"2770_CR207","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.3390\/ijms25115806","volume":"25","author":"R \u015awiechowski","year":"2024","unstructured":"\u015awiechowski, R. et al. Genetic insights into colorectal cancer: evaluating PI3K\/AKT signaling pathway genes expression. Int. J. Mol. Sci. 25, 5806 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR208","doi-asserted-by":"publisher","first-page":"44113","DOI":"10.1074\/jbc.M405323200","volume":"279","author":"G Dufour","year":"2004","unstructured":"Dufour, G. et al. Human intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation and roles of protein kinase B\/Akt isoforms. J. Biol. Chem. 279, 44113\u201344122 (2004).","journal-title":"J. Biol. Chem."},{"key":"2770_CR209","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1038\/onc.2016.460","volume":"36","author":"E Agarwal","year":"2017","unstructured":"Agarwal, E. et al. Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis. Oncogene. 36, 3104\u20133118 (2017).","journal-title":"Oncogene."},{"key":"2770_CR210","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.semcancer.2017.07.007","volume":"50","author":"CG Kim","year":"2018","unstructured":"Kim, C. G. et al. Role of forkhead box class O proteins in cancer progression and metastasis. Semin. Cancer Biol. 50, 142\u2013151 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR211","doi-asserted-by":"publisher","first-page":"153150","DOI":"10.1016\/j.prp.2020.153150","volume":"216","author":"YS Ko","year":"2020","unstructured":"Ko, Y. S., Kim, N. Y. & Pyo, J. S. Clinicopathological significance and angiogenic role of the constitutive phosphorylation of the FOXO1 transcription factor in colorectal cancer. Pathol. Res. Pract. 216, 153150 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"2770_CR212","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","volume":"133","author":"L Salmena","year":"2008","unstructured":"Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403\u2013414 (2008).","journal-title":"Cell"},{"key":"2770_CR213","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-016-0228-5","volume":"23","author":"Y Yazdani","year":"2016","unstructured":"Yazdani, Y., Farazmandfar, T., Azadeh, H. & Zekavatian, Z. The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J. Biomed. Sci. 23, 9 (2016).","journal-title":"J. Biomed. Sci."},{"key":"2770_CR214","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(09)60617-6","volume":"374","author":"HH Hartgrink","year":"2009","unstructured":"Hartgrink, H. H., Jansen, E. P., van Grieken, N. C. & van de Velde, C. J. Gastric cancer. Lancet 374, 477\u2013490 (2009).","journal-title":"Lancet"},{"key":"2770_CR215","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth, E. C. et al. Gastric cancer. Lancet 396, 635\u2013648 (2020).","journal-title":"Lancet"},{"key":"2770_CR216","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/annonc\/mdw040","volume":"27","author":"NY Chia","year":"2016","unstructured":"Chia, N. Y. & Tan, P. Molecular classification of gastric cancer. Ann. Oncol. 27, 763\u2013769 (2016).","journal-title":"Ann. Oncol."},{"key":"2770_CR217","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1002\/ptr.7820","volume":"37","author":"P He","year":"2023","unstructured":"He, P. et al. Thymoquinone induces apoptosis and protective autophagy in gastric cancer cells by inhibiting the PI3K\/Akt\/mTOR pathway. Phytother. Res. 37, 3467\u20133480 (2023).","journal-title":"Phytother. Res."},{"key":"2770_CR218","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/annonc\/mdx047","volume":"28","author":"C B\u00f6ger","year":"2017","unstructured":"B\u00f6ger, C. et al. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann. Oncol. 28, 1005\u20131014 (2017).","journal-title":"Ann. Oncol."},{"key":"2770_CR219","first-page":"3607","volume":"9","author":"M Liang","year":"2015","unstructured":"Liang, M. et al. Downregulation of miR203 induces overexpression of PIK3CA and predicts poor prognosis of gastric cancer patients. Drug Des. Devel. Ther. 9, 3607\u20133616 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"2770_CR220","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.3748\/wjg.v16.i39.4986","volume":"16","author":"JF Liu","year":"2010","unstructured":"Liu, J. F. et al. Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J. Gastroenterol. 16, 4986\u20134991 (2010).","journal-title":"World J. Gastroenterol."},{"key":"2770_CR221","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1750-3639.2003.tb00481.x","volume":"13","author":"CB Knobbe","year":"2003","unstructured":"Knobbe, C. B. & Reifenberger, G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3\u2019-kinase\/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507\u2013518 (2003).","journal-title":"Brain Pathol."},{"key":"2770_CR222","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1073\/pnas.84.14.5034","volume":"84","author":"SP Staal","year":"1987","unstructured":"Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 84, 5034\u20135037 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR223","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00432-014-1663-x","volume":"140","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. A GG allele of 3\u2019-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer. J. Cancer Res. Clin. Oncol. 140, 1399\u20131411 (2014).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2770_CR224","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/modpathol.3800789","volume":"20","author":"JH Kim","year":"2007","unstructured":"Kim, J. H. et al. Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer. Mod. Pathol. 20, 835\u2013842 (2007).","journal-title":"Mod. Pathol."},{"key":"2770_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01839-2","volume":"22","author":"L An","year":"2023","unstructured":"An, L., Li, M. & Jia, Q. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma. Mol. Cancer 22, 140 (2023).","journal-title":"Mol. Cancer"},{"key":"2770_CR226","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan, E. et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163, 649\u2013658 (2022).","journal-title":"Gastroenterology"},{"key":"2770_CR227","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7150\/ijbs.53795","volume":"17","author":"JC Xu","year":"2021","unstructured":"Xu, J. C. et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K\/AKT and ERK pathway. Int. J. Biol. Sci. 17, 259\u2013270 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR228","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.biopha.2018.05.149","volume":"105","author":"Q Guanen","year":"2018","unstructured":"Guanen, Q. et al. MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K\/AKT\/mTOR signaling pathway. Biomed. Pharmacother. 105, 350\u2013361 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2770_CR229","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2019.10.004","volume":"468","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. SOX9\/miR-203a axis drives PI3K\/AKT signaling to promote esophageal cancer progression. Cancer Lett. 468, 14\u201326 (2020).","journal-title":"Cancer Lett."},{"key":"2770_CR230","doi-asserted-by":"publisher","first-page":"11535","DOI":"10.7150\/thno.45261","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma. Theranostics. 10, 11535\u201311548 (2020).","journal-title":"Theranostics."},{"key":"2770_CR231","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-12-3559","volume":"19","author":"H Shigaki","year":"2013","unstructured":"Shigaki, H. et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin. Cancer Res. 19, 2451\u20132459 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR232","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/cbin.11847","volume":"46","author":"W Xu","year":"2022","unstructured":"Xu, W. et al. PIK3CB promotes oesophageal cancer proliferation through the PI3K\/AKT\/mTOR signalling axis. Cell Biol. Int. 46, 1399\u20131408 (2022).","journal-title":"Cell Biol. Int."},{"key":"2770_CR233","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13046-015-0212-z","volume":"34","author":"Z Zhu","year":"2015","unstructured":"Zhu, Z. et al. Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 34, 95 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR234","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann, D., Park, S. & Hall, M. N. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Rev. Cancer. 18, 744\u2013757 (2018).","journal-title":"Nat. Rev. Cancer."},{"key":"2770_CR235","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.biopha.2018.03.106","volume":"102","author":"X Zhu","year":"2018","unstructured":"Zhu, X. et al. Osthole inhibits the PI3K\/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma. Biomed. Pharmacother. 102, 502\u2013509 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2770_CR236","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1007\/s11033-022-07246-y","volume":"49","author":"R Qiu","year":"2022","unstructured":"Qiu, R., Wang, W., Li, J. & Wang, Y. Roles of PTEN inactivation and PD-1\/PD-L1 activation in esophageal squamous cell carcinoma. Mol. Biol. Rep. 49, 6633\u20136645 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"2770_CR237","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10620-010-1474-0","volume":"56","author":"G Hou","year":"2011","unstructured":"Hou, G. et al. Mutational analysis of the PTEN gene and its effects in esophageal squamous cell carcinoma. Dig. Dis. Sci. 56, 1315\u20131322 (2011).","journal-title":"Dig. Dis. Sci."},{"key":"2770_CR238","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent, A. et al. Pancreatic cancer. Lancet 378, 607\u2013620 (2011).","journal-title":"Lancet"},{"key":"2770_CR239","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein, A. P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat. Rev. Gastroenterol. Hepatol. 18, 493\u2013502 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2770_CR240","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 164, 752\u2013765 (2023).","journal-title":"Gastroenterology."},{"key":"2770_CR241","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/0008-5472.CAN-12-1726","volume":"73","author":"F Janku","year":"2013","unstructured":"Janku, F. et al. PIK3CA mutation H1047R is associated with response to PI3K\/AKT\/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 73, 276\u2013284 (2013).","journal-title":"Cancer Res."},{"key":"2770_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.28","volume":"4","author":"SN Payne","year":"2015","unstructured":"Payne, S. N. et al. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis 4, e169 (2015).","journal-title":"Oncogenesis"},{"key":"2770_CR243","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","volume":"95","author":"V Stambolic","year":"1998","unstructured":"Stambolic, V. et al. Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29\u201339 (1998).","journal-title":"Cell"},{"key":"2770_CR244","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11010-009-0154-x","volume":"331","author":"J Ma","year":"2009","unstructured":"Ma, J. et al. PTEN regulates angiogenesis through PI3K\/Akt\/VEGF signaling pathway in human pancreatic cancer cells. Mol. Cell. Biochem. 331, 161\u2013171 (2009).","journal-title":"Mol. Cell. Biochem."},{"key":"2770_CR245","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","volume":"365","author":"U Veronesi","year":"2005","unstructured":"Veronesi, U. et al. Breast cancer. Lancet 365, 1727\u20131741 (2005).","journal-title":"Lancet"},{"key":"2770_CR246","first-page":"439","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis, C. E. et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J. Clin. 67, 439\u2013448 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"2770_CR247","doi-asserted-by":"publisher","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman, K. et al. Breast cancer: biology, biomarkers, and treatments. Int. Immunopharmacol. 84, 106535 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2770_CR248","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1038\/527S101a","volume":"527","author":"C Woolston","year":"2015","unstructured":"Woolston, C. Breast cancer. Nature 527, S101 (2015).","journal-title":"Nature"},{"key":"2770_CR249","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","volume":"46","author":"N Jokar","year":"2021","unstructured":"Jokar, N. et al. Theranostic approach in breast cancer: a treasured tailor for future oncology. Clin. Nucl. Med. 46, e410\u2013e420 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"2770_CR250","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3605","volume":"16","author":"D Zardavas","year":"2014","unstructured":"Zardavas, D., Phillips, W. A. & Loi, S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res. 16, 201 (2014).","journal-title":"Breast Cancer Res."},{"key":"2770_CR251","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1073\/pnas.0907011107","volume":"107","author":"S Loi","year":"2010","unstructured":"Loi, S. et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl. Acad. Sci. USA 107, 10208\u201310213 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR252","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","volume":"11","author":"DA Levine","year":"2005","unstructured":"Levine, D. A. et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11, 2875\u20132878 (2005).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR253","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1073\/pnas.1303204110","volume":"110","author":"AB Hanker","year":"2013","unstructured":"Hanker, A. B. et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 110, 14372\u201314377 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR254","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1158\/0008-5472.CAN-15-2201","volume":"76","author":"Y Nakanishi","year":"2016","unstructured":"Nakanishi, Y. et al. Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110\u03b2. Cancer Res. 76, 1193\u20131203 (2016).","journal-title":"Cancer Res."},{"key":"2770_CR255","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare, D. A. & Testa, J. R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455\u20137464 (2005).","journal-title":"Oncogene"},{"key":"2770_CR256","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1073\/pnas.0605874104","volume":"104","author":"X Ju","year":"2007","unstructured":"Ju, X. et al. Akt1 governs breast cancer progression in vivo. Proc. Natl. Acad. Sci. USA 104, 7438\u20137443 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2770_CR257","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/bcr739","volume":"6","author":"NM Chau","year":"2004","unstructured":"Chau, N. M. & Ashcroft, M. Akt2: a role in breast cancer metastasis. Breast Cancer Res. 6, 55\u201357 (2004).","journal-title":"Breast Cancer Res."},{"key":"2770_CR258","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.ejca.2012.12.006","volume":"49","author":"H Fohlin","year":"2013","unstructured":"Fohlin, H. et al. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. Eur. J. Cancer. 49, 1196\u20131204 (2013).","journal-title":"Eur. J. Cancer."},{"key":"2770_CR259","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/his.12313","volume":"64","author":"G O\u2019Hurley","year":"2014","unstructured":"O\u2019Hurley, G. et al. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 64, 660\u2013670 (2014).","journal-title":"Histopathology"},{"key":"2770_CR260","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho, K. R. & Shih Ie, M. Ovarian cancer. Annu. Rev. Pathol. 4, 287\u2013313 (2009).","journal-title":"Annu. Rev. Pathol."},{"key":"2770_CR261","first-page":"297","volume":"49","author":"EE Partridge","year":"1999","unstructured":"Partridge, E. E. & Barnes, M. N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J. Clin. 49, 297\u2013320 (1999).","journal-title":"CA Cancer J. Clin."},{"key":"2770_CR262","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.3390\/ijms14048213","volume":"14","author":"ZC Dobbin","year":"2013","unstructured":"Dobbin, Z. C. & Landen, C. N. The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer. Int. J. Mol. Sci. 14, 8213\u20138227 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR263","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41379-021-00861-3","volume":"34","author":"K Murakami","year":"2021","unstructured":"Murakami, K. et al. Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. Mod. Pathol. 34, 2071\u20132079 (2021).","journal-title":"Mod. Pathol."},{"key":"2770_CR264","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2019.10.021","volume":"469","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Lett. 469, 54\u201367 (2020).","journal-title":"Cancer Lett."},{"key":"2770_CR265","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cellsig.2018.01.021","volume":"45","author":"B Zheng","year":"2018","unstructured":"Zheng, B. et al. AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3\/NF-\u03baB axis. Cell. Signal. 45, 122\u2013131 (2018).","journal-title":"Cell. Signal."},{"key":"2770_CR266","doi-asserted-by":"publisher","first-page":"58","DOI":"10.6004\/jnccn.2008.0007","volume":"6","author":"EE Partridge","year":"2008","unstructured":"Partridge, E. E. et al. Cervical cancer screening. J. Natl. Compr. Canc. Netw. 6, 58\u201382 (2008).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2770_CR267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd, E. M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16, 1\u201317 (2003).","journal-title":"Clin. Microbiol. Rev."},{"key":"2770_CR268","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0361-x","volume":"14","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. The role of the PI3K\/Akt\/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol. Cancer. 14, 87 (2015).","journal-title":"Mol. Cancer."},{"key":"2770_CR269","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-71","volume":"10","author":"FE Henken","year":"2011","unstructured":"Henken, F. E. et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol. Cancer. 10, 71 (2011).","journal-title":"Mol. Cancer."},{"key":"2770_CR270","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-018-0674-5","volume":"11","author":"W Jiang","year":"2018","unstructured":"Jiang, W. et al. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the \u03b2-catenin\/SIRT3 signaling pathway in cervical cancer. J. Hematol. Oncol. 11, 139 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2770_CR271","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13046-018-0744-0","volume":"37","author":"S Li","year":"2018","unstructured":"Li, S., Ma, Y. M., Zheng, P. S. & Zhang, P. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1\/2 through the receptor ErbB2. J. Exp. Clin. Cancer Res. 37, 80 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR272","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","volume":"11","author":"AJ Chang","year":"2014","unstructured":"Chang, A. J., Autio, K. A., Roach, M. 3rd & Scher, H. I. High-risk prostate cancer-classification and therapy. Nat. Rev. Clin. Oncol. 11, 308\u2013323 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2770_CR273","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren, O. et al. 2022 Update on prostate cancer epidemiology and risk factors-a systematic review. Eur. Urol. 84, 191\u2013206 (2023).","journal-title":"Eur. Urol."},{"key":"2770_CR274","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning, B. Y., Dass, M. S., Smalley, M. J. & Pearson, H. B. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int. J. Mol. Sci. 21, 4507 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR275","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","volume":"19","author":"DJ Mulholland","year":"2011","unstructured":"Mulholland, D. J. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 19, 792\u2013804 (2011).","journal-title":"Cancer Cell."},{"key":"2770_CR276","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41388-023-02875-4","volume":"43","author":"KA Miller","year":"2024","unstructured":"Miller, K. A. et al. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. Oncogene. 43, 22\u201334 (2024).","journal-title":"Oncogene."},{"key":"2770_CR277","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2020.04.058","volume":"78","author":"C Herberts","year":"2020","unstructured":"Herberts, C. et al. Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer. Eur. Urol. 78, 834\u2013844 (2020).","journal-title":"Eur. Urol."},{"key":"2770_CR278","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","volume":"8","author":"HB Pearson","year":"2018","unstructured":"Pearson, H. B. et al. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with pten loss to accelerate progression and castration-resistant growth. Cancer Discov. 8, 764\u2013779 (2018).","journal-title":"Cancer Discov."},{"key":"2770_CR279","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1158\/2159-8290.CD-18-0369","volume":"8","author":"J Triscott","year":"2018","unstructured":"Triscott, J. & Rubin, M. A. Prostate power play: does Pik3ca accelerate pten-deficient cancer progression? Cancer Discov. 8, 682\u2013685 (2018).","journal-title":"Cancer Discov."},{"key":"2770_CR280","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41420-023-01625-5","volume":"9","author":"H Bi","year":"2023","unstructured":"Bi, H. et al. Knockdown of KIF15 suppresses proliferation of prostate cancer cells and induces apoptosis through PI3K\/Akt signaling pathway. Cell Death Discov. 9, 326 (2023).","journal-title":"Cell Death Discov."},{"key":"2770_CR281","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat Rev Dis. Primers. 9, 58 (2023).","journal-title":"Nat Rev Dis. Primers."},{"key":"2770_CR282","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber, I. et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur. Urol. 84, 176\u2013190 (2023).","journal-title":"Eur. Urol."},{"key":"2770_CR283","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig, T. W. et al. NCCN Guidelines\u00ae Insights: bladder cancer, version 3.2024. J. Natl. Compr. Canc. Netw. 22, 216\u2013225 (2024).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2770_CR284","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/ijc.28518","volume":"134","author":"J Calderaro","year":"2014","unstructured":"Calderaro, J. et al. PI3K\/AKT pathway activation in bladder carcinogenesis. Int. J. Cancer. 134, 1776\u20131784 (2014).","journal-title":"Int. J. Cancer."},{"key":"2770_CR285","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","volume":"145","author":"N Hou\u00e9d\u00e9","year":"2015","unstructured":"Hou\u00e9d\u00e9, N. & Pourquier, P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol. Ther. 145, 1\u201318 (2015).","journal-title":"Pharmacol. Ther."},{"key":"2770_CR286","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","volume":"15","author":"FM Platt","year":"2009","unstructured":"Platt, F. M. et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 15, 6008\u20136017 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR287","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.ajpath.2023.07.001","volume":"193","author":"L Shuman","year":"2023","unstructured":"Shuman, L. et al. Urothelium-specific expression of mutationally activated Pik3ca initiates early lesions of noninvasive bladder cancer. Am. J. Pathol. 193, 2133\u20132143 (2023).","journal-title":"Am. J. Pathol."},{"key":"2770_CR288","doi-asserted-by":"publisher","first-page":"173226","DOI":"10.1016\/j.ejphar.2020.173226","volume":"881","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh, M., Zarrabi, A., Samarghandian, S. & Najafi, M. PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer? Eur. J. Pharmacol. 881, 173226 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"2770_CR289","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13404","volume":"56","author":"Y Su","year":"2023","unstructured":"Su, Y. et al. YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer. Cell Prolif. 56, e13404 (2023).","journal-title":"Cell Prolif."},{"key":"2770_CR290","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/bjc.2017.393","volume":"118","author":"E Kashiwagi","year":"2018","unstructured":"Kashiwagi, E. et al. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. Br. J. Cancer. 118, 213\u2013223 (2018).","journal-title":"Br. J. Cancer."},{"key":"2770_CR291","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13046-024-02966-4","volume":"43","author":"T Li","year":"2024","unstructured":"Li, T. et al. Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation. J. Exp. Clin. Cancer Res. 43, 50 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR292","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/1078-0432.CCR-23-1892","volume":"30","author":"I Lyskj\u00e6r","year":"2024","unstructured":"Lyskj\u00e6r, I. et al. Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic. Clin. Cancer Res. 30, 663\u2013672 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR293","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet. 373, 1119\u20131132 (2009).","journal-title":"Lancet."},{"key":"2770_CR294","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/j.juro.2009.08.085","volume":"182","author":"C Porta","year":"2009","unstructured":"Porta, C. & Figlin, R. A. Phosphatidylinositol-3-kinase\/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase\/Akt inhibitors. J. Urol. 182, 2569\u20132577 (2009).","journal-title":"J. Urol."},{"key":"2770_CR295","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326 (2018).","journal-title":"Cell Rep."},{"key":"2770_CR296","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdi182","volume":"16","author":"S Hara","year":"2005","unstructured":"Hara, S. et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 16, 928\u2013933 (2005).","journal-title":"Ann. Oncol."},{"key":"2770_CR297","doi-asserted-by":"publisher","first-page":"115020","DOI":"10.1016\/j.jep.2022.115020","volume":"288","author":"T Wang","year":"2022","unstructured":"Wang, T. et al. Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN\/PI3K\/AKT pathway. J. Ethnopharmacol. 288, 115020 (2022).","journal-title":"J. Ethnopharmacol."},{"key":"2770_CR298","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1072-5","volume":"18","author":"D Xue","year":"2019","unstructured":"Xue, D. et al. Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p\/E-cadherin signals. Mol. Cancer. 18, 151 (2019).","journal-title":"Mol. Cancer."},{"key":"2770_CR299","first-page":"620","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi, Z. et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 73, 620\u2013652 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2770_CR300","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A. et al. Lung cancer. Lancet. 398, 535\u2013554 (2021).","journal-title":"Lancet."},{"key":"2770_CR301","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 187, 184\u2013203 (2024).","journal-title":"Cell."},{"key":"2770_CR302","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.canlet.2009.03.038","volume":"283","author":"T Shibata","year":"2009","unstructured":"Shibata, T., Kokubu, A., Tsuta, K. & Hirohashi, S. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett. 283, 203\u2013211 (2009).","journal-title":"Cancer Lett."},{"key":"2770_CR303","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","volume":"28","author":"Y Jin","year":"2022","unstructured":"Jin, Y. et al. Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer. Clin. Cancer Res. 28, 526\u2013539 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR304","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06171-7","volume":"14","author":"H Deng","year":"2023","unstructured":"Deng, H. et al. PI3K\/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer. Cell Death Dis. 14, 652 (2023).","journal-title":"Cell Death Dis."},{"key":"2770_CR305","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446\u2013454 (2018).","journal-title":"Nature"},{"key":"2770_CR306","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2165\/11597700-000000000-00000","volume":"71","author":"L Bonanno","year":"2011","unstructured":"Bonanno, L. et al. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 71, 2231\u20132246 (2011).","journal-title":"Drugs"},{"key":"2770_CR307","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04703-5","volume":"21","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K\/AKT\/mTOR signaling pathway. J. Transl. Med. 21, 819 (2023).","journal-title":"J. Transl. Med."},{"key":"2770_CR308","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175\u2013180 (2011).","journal-title":"Lancet Oncol."},{"key":"2770_CR309","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1158\/0008-5472.CAN-22-3023","volume":"83","author":"F Exposito","year":"2023","unstructured":"Exposito, F. et al. PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer Res. 83, 2513\u20132526 (2023).","journal-title":"Cancer Res."},{"key":"2770_CR310","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.phrs.2024.107123","volume":"202","author":"X Liu","year":"2024","unstructured":"Liu, X., Mei, W., Zhang, P. & Zeng, C. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities. Pharmacol. Res. 202, 107123 (2024).","journal-title":"Pharmacol. Res."},{"key":"2770_CR311","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/cam4.852","volume":"5","author":"Z Song","year":"2016","unstructured":"Song, Z., Yu, X. & Zhang, Y. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. Cancer Med. 5, 2694\u20132700 (2016).","journal-title":"Cancer Med."},{"key":"2770_CR312","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00408-008-9130-6","volume":"187","author":"C Wang","year":"2009","unstructured":"Wang, C., Yang, R., Yue, D. & Zhang, Z. Expression of FAK and PTEN in bronchioloalveolar carcinoma and lung adenocarcinoma. Lung 187, 104\u2013109 (2009).","journal-title":"Lung"},{"key":"2770_CR313","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","volume":"69","author":"ML Sos","year":"2009","unstructured":"Sos, M. L. et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256\u20133261 (2009).","journal-title":"Cancer Res."},{"key":"2770_CR314","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/j.1349-7006.2011.02025.x","volume":"102","author":"MW Lee","year":"2011","unstructured":"Lee, M. W. et al. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci. 102, 1822\u20131828 (2011).","journal-title":"Cancer Sci."},{"key":"2770_CR315","doi-asserted-by":"publisher","first-page":"14032","DOI":"10.1021\/acs.jmedchem.2c01246","volume":"65","author":"F Xu","year":"2022","unstructured":"Xu, F. et al. Discovery of isoform-selective Akt3 degraders overcoming osimertinib-induced resistance in non-small cell lung cancer cells. J. Med. Chem. 65, 14032\u201314048 (2022).","journal-title":"J. Med. Chem."},{"key":"2770_CR316","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41568-019-0226-5","volume":"20","author":"J Bi","year":"2020","unstructured":"Bi, J. et al. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat. Rev. Cancer. 20, 57\u201370 (2020).","journal-title":"Nat. Rev. Cancer."},{"key":"2770_CR317","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1750-3639.2004.tb00080.x","volume":"14","author":"M Mizoguchi","year":"2004","unstructured":"Mizoguchi, M., Nutt, C. L., Mohapatra, G. & Louis, D. N. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 14, 372\u2013377 (2004).","journal-title":"Brain Pathol."},{"key":"2770_CR318","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","unstructured":"Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","journal-title":"Nature"},{"key":"2770_CR319","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.3390\/ijms26115276","volume":"26","author":"A Tom\u00e1s","year":"2025","unstructured":"Tom\u00e1s, A. & Pojo, M. PIK3CA mutations: are they a relevant target in adult diffuse gliomas? Int. J. Mol. Sci. 26, 5276 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR320","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/neuonc\/nox181","volume":"20","author":"KJ Pridham","year":"2018","unstructured":"Pridham, K. J. et al. PIK3CB\/p110\u03b2 is a selective survival factor for glioblastoma. Neuro Oncol. 20, 494\u2013505 (2018).","journal-title":"Neuro Oncol."},{"key":"2770_CR321","doi-asserted-by":"publisher","first-page":"718621","DOI":"10.3389\/fimmu.2021.718621","volume":"12","author":"S Chandrasekaran","year":"2021","unstructured":"Chandrasekaran, S. et al. Strategies to overcome failures in T-cell immunotherapies by targeting PI3K-\u03b4 and -\u03b3. Front. Immunol. 12, 718621 (2021).","journal-title":"Front. Immunol."},{"key":"2770_CR322","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/neuonc\/nop026","volume":"12","author":"H Mure","year":"2010","unstructured":"Mure, H. et al. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol. 12, 221\u2013232 (2010).","journal-title":"Neuro Oncol."},{"key":"2770_CR323","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ijc.24314","volume":"125","author":"B Zhang","year":"2009","unstructured":"Zhang, B. et al. Reduction of Akt2 inhibits migration and invasion of glioma cells. Int. J. Cancer. 125, 585\u2013595 (2009).","journal-title":"Int. J. Cancer."},{"key":"2770_CR324","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550\u2013563 (2016).","journal-title":"Cell"},{"key":"2770_CR325","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"2770_CR326","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.18.01207","volume":"37","author":"PY Wen","year":"2019","unstructured":"Wen, P. Y. et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial. J. Clin. Oncol. 37, 741\u2013750 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2770_CR327","doi-asserted-by":"publisher","first-page":"7979","DOI":"10.3390\/ijms25147979","volume":"25","author":"E Agosti","year":"2024","unstructured":"Agosti, E. et al. Glioma stem cells as promoter of glioma progression: a systematic review of molecular pathways and targeted therapies. Int. J. Mol. Sci. 25, 7979 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR328","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0565-4","volume":"18","author":"B Haas","year":"2018","unstructured":"Haas, B. et al. Inhibition of the PI3K but not the MEK\/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int. 18, 69 (2018).","journal-title":"Cancer Cell Int."},{"key":"2770_CR329","doi-asserted-by":"publisher","first-page":"105451","DOI":"10.1016\/j.oraloncology.2021.105451","volume":"121","author":"A Chamoli","year":"2021","unstructured":"Chamoli, A. et al. Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics. Oral Oncol. 121, 105451 (2021).","journal-title":"Oral Oncol."},{"key":"2770_CR330","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1097\/JS9.0000000000000489","volume":"109","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). Int. J. Surg. 109, 2220\u20132227 (2023).","journal-title":"Int. J. Surg."},{"key":"2770_CR331","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/ijms22010240","volume":"22","author":"N Kitamura","year":"2020","unstructured":"Kitamura, N. et al. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma. Int. J. Mol. Sci. 22, 240 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR332","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2019.09.011","volume":"61","author":"AWY Chai","year":"2020","unstructured":"Chai, A. W. Y., Lim, K. P. & Cheong, S. C. Translational genomics and recent advances in oral squamous cell carcinoma. Semin. Cancer Biol. 61, 71\u201383 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR333","doi-asserted-by":"publisher","first-page":"264","DOI":"10.20892\/j.issn.2095-3941.2018.0257","volume":"16","author":"NS Zainal","year":"2019","unstructured":"Zainal, N. S. et al. Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. Cancer Biol. Med. 16, 264\u2013275 (2019).","journal-title":"Cancer Biol. Med."},{"key":"2770_CR334","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/j.oraloncology.2009.06.003","volume":"45","author":"A Iamaroon","year":"2009","unstructured":"Iamaroon, A. & Krisanaprakornkit, S. Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol. 45, e175\u2013e179 (2009).","journal-title":"Oral Oncol."},{"key":"2770_CR335","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers. 6, 92 (2020).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"2770_CR336","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","volume":"52","author":"B Solomon","year":"2018","unstructured":"Solomon, B., Young, R. J. & Rischin, D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin. Cancer Biol. 52, 228\u2013240 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR337","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer. 149, 778\u2013789 (2021).","journal-title":"Int. J. Cancer."},{"key":"2770_CR338","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7150\/ijbs.66841","volume":"18","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. As a novel tumor suppressor, LHPP promotes apoptosis by inhibiting the PI3K\/AKT signaling pathway in oral squamous cell carcinoma. Int. J. Biol. Sci. 18, 491\u2013506 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR339","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf2911","volume":"374","author":"DL Swaney","year":"2021","unstructured":"Swaney, D. L. et al. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science. 374, eabf2911 (2021).","journal-title":"Science."},{"key":"2770_CR340","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1038\/onc.2016.1","volume":"35","author":"L Du","year":"2016","unstructured":"Du, L. et al. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF\u03b2 signaling. Oncogene. 35, 4641\u20134652 (2016).","journal-title":"Oncogene."},{"key":"2770_CR341","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1111\/cas.14911","volume":"112","author":"H Takahashi","year":"2021","unstructured":"Takahashi, H. et al. AKT3 is a key regulator of head and neck squamous cell carcinoma. Cancer Sci. 112, 2325\u20132334 (2021).","journal-title":"Cancer Sci."},{"key":"2770_CR342","doi-asserted-by":"publisher","first-page":"110714","DOI":"10.1016\/j.intimp.2023.110714","volume":"123","author":"RM Deng","year":"2023","unstructured":"Deng, R. M. & Zhou, J. The role of PI3K\/AKT signaling pathway in myocardial ischemia-reperfusion injury. Int. Immunopharmacol. 123, 110714 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2770_CR343","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1083\/jcb.95.1.333","volume":"95","author":"G Greenburg","year":"1982","unstructured":"Greenburg, G. & Hay, E. D. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95, 333\u2013339 (1982).","journal-title":"J. Cell Biol."},{"key":"2770_CR344","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2770_CR345","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1096\/fj.201600388R","volume":"30","author":"X Chen","year":"2016","unstructured":"Chen, X., Bode, A. M., Dong, Z. & Cao, Y. The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer. FASEB J. 30, 3001\u20133010 (2016).","journal-title":"FASEB J."},{"key":"2770_CR346","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/med.21948","volume":"43","author":"HL Ang","year":"2023","unstructured":"Ang, H. L. et al. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Med. Res. Rev. 43, 1141\u20131200 (2023).","journal-title":"Med. Res. Rev."},{"key":"2770_CR347","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pharmthera.2015.01.004","volume":"150","author":"L Li","year":"2015","unstructured":"Li, L. & Li, W. Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol. Ther. 150, 33\u201346 (2015).","journal-title":"Pharmacol. Ther."},{"key":"2770_CR348","doi-asserted-by":"publisher","first-page":"11386","DOI":"10.3390\/ijms241411386","volume":"24","author":"G Manfioletti","year":"2023","unstructured":"Manfioletti, G. & Fedele, M. Epithelial-mesenchymal transition (EMT). Int. J. Mol. Sci. 24, 11386 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR349","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","volume":"13","author":"V Mittal","year":"2018","unstructured":"Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 13, 395\u2013412 (2018).","journal-title":"Annu. Rev. Pathol."},{"key":"2770_CR350","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.522","volume":"11","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Apolipoprotein C-II induces EMT to promote gastric cancer peritoneal metastasis via PI3K\/AKT\/mTOR pathway. Clin Transl. Med. 11, e522 (2021).","journal-title":"Clin Transl. Med."},{"key":"2770_CR351","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1083\/jcb.148.4.779","volume":"148","author":"RB Hazan","year":"2000","unstructured":"Hazan, R. B. et al. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell Biol. 148, 779\u2013790 (2000).","journal-title":"J. Cell Biol."},{"key":"2770_CR352","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-07-1263","volume":"13","author":"K Gravdal","year":"2007","unstructured":"Gravdal, K., Halvorsen, O. J., Haukaas, S. A. & Akslen, L. A. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 13, 7003\u20137011 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR353","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2147\/DDDT.S251614","volume":"14","author":"R Wang","year":"2020","unstructured":"Wang, R., Lu, X. & Yu, R. Lycopene inhibits epithelial-mesenchymal transition and promotes apoptosis in oral cancer via PI3K\/AKT\/m-TOR signal pathway. Drug Des. Devel. Ther. 14, 2461\u20132471 (2020).","journal-title":"Drug Des. Devel. Ther."},{"key":"2770_CR354","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13402-016-0308-2","volume":"40","author":"S Bugide","year":"2017","unstructured":"Bugide, S. et al. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K\/AKT pathway activation. Cell Oncol. 40, 133\u2013144 (2017).","journal-title":"Cell Oncol."},{"key":"2770_CR355","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","volume":"41","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages. J. Exp. Clin. Cancer Res. 41, 303 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR356","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert, B. et al. Lactate metabolism in human lung tumors. Cell 171, 358\u2013371 (2017).","journal-title":"Cell"},{"key":"2770_CR357","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/ijms22041534","volume":"22","author":"N Abdel Hadi","year":"2021","unstructured":"Abdel Hadi, N., Reyes-Castellanos, G. & Carrier, A. Targeting redox metabolism in pancreatic cancer. Int. J. Mol. Sci. 22, 1534 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR358","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcdb.2019.05.027","volume":"98","author":"M Thapa","year":"2020","unstructured":"Thapa, M. & Dallmann, G. Role of coenzymes in cancer metabolism. Semin. Cell Dev. Biol. 98, 44\u201353 (2020).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2770_CR359","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"2770_CR360","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441\u2013464 (2011).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"2770_CR361","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1101\/gad.889901","volume":"15","author":"K Gottlob","year":"2001","unstructured":"Gottlob, K. et al. Inhibition of early apoptotic events by Akt\/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15, 1406\u20131418 (2001).","journal-title":"Genes Dev."},{"key":"2770_CR362","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","volume":"64","author":"RL Elstrom","year":"2004","unstructured":"Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892\u20133899 (2004).","journal-title":"Cancer Res."},{"key":"2770_CR363","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell. 149, 274\u2013293 (2012).","journal-title":"Cell."},{"key":"2770_CR364","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross, D. A. et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785\u2013789 (1995).","journal-title":"Nature"},{"key":"2770_CR365","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1471-4914(02)02317-1","volume":"8","author":"GL Semenza","year":"2002","unstructured":"Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8, S62\u2013S67 (2002).","journal-title":"Trends Mol. Med."},{"key":"2770_CR366","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2019.10.029","volume":"469","author":"T Gao","year":"2020","unstructured":"Gao, T. et al. SIK2 promotes reprogramming of glucose metabolism through PI3K\/AKT\/HIF-1\u03b1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer. Cancer Lett. 469, 89\u2013101 (2020).","journal-title":"Cancer Lett."},{"key":"2770_CR367","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","volume":"41","author":"S Dong","year":"2022","unstructured":"Dong, S. et al. ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J. Exp. Clin. Cancer Res. 41, 15 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR368","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1084\/jem.185.8.1467","volume":"185","author":"Y Higashi","year":"1997","unstructured":"Higashi, Y. et al. Impairment of T cell development in deltaEF1 mutant mice. J. Exp. Med. 185, 1467\u20131479 (1997).","journal-title":"J. Exp. Med."},{"key":"2770_CR369","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04632-z","volume":"13","author":"H Jiang","year":"2022","unstructured":"Jiang, H. et al. Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer. Cell Death Dis. 13, 206 (2022).","journal-title":"Cell Death Dis."},{"key":"2770_CR370","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41388-019-1052-7","volume":"39","author":"G Zhangyuan","year":"2020","unstructured":"Zhangyuan, G. et al. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway. Oncogene. 39, 1213\u20131230 (2020).","journal-title":"Oncogene."},{"key":"2770_CR371","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03596-w","volume":"12","author":"X Luo","year":"2021","unstructured":"Luo, X. et al. The fatty acid receptor CD36 promotes HCC progression through activating Src\/PI3K\/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 12, 328 (2021).","journal-title":"Cell Death Dis."},{"key":"2770_CR372","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03719-3","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K\/AKT\/mTOR pathway. Cell Death Dis. 12, 433 (2021).","journal-title":"Cell Death Dis."},{"key":"2770_CR373","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature. 575, 299\u2013309 (2019).","journal-title":"Nature."},{"key":"2770_CR374","doi-asserted-by":"publisher","first-page":"216307","DOI":"10.1016\/j.canlet.2023.216307","volume":"570","author":"Y Qin","year":"2023","unstructured":"Qin, Y. et al. Autophagy and cancer drug resistance in dialogue: pre-clinical and clinical evidence. Cancer Lett. 570, 216307 (2023).","journal-title":"Cancer Lett."},{"key":"2770_CR375","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615\u2013627 (2002).","journal-title":"Annu. Rev. Med."},{"key":"2770_CR376","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13046-023-02792-0","volume":"42","author":"K Lin","year":"2023","unstructured":"Lin, K. et al. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN\/PI3K\/AKT pathway. J. Exp. Clin. Cancer Res. 42, 217 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR377","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ijbiomac.2017.10.154","volume":"107","author":"C Cheng","year":"2018","unstructured":"Cheng, C. et al. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K\/Akt and Wnt\/\u03b2-catenin signaling pathways by up-regulating miR-34a. Int. J. Biol. Macromol. 107, 2620\u20132629 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"2770_CR378","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-023-00368-8","volume":"18","author":"C Xu","year":"2023","unstructured":"Xu, C., Ye, Q., Ye, C. & Liu, S. circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K\/AKT signaling pathway. Biol. Direct. 18, 14 (2023).","journal-title":"Biol. Direct."},{"key":"2770_CR379","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02118-0","volume":"21","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. [6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K\/AKT signaling. Cancer Cell Int. 21, 420 (2021).","journal-title":"Cancer Cell Int."},{"key":"2770_CR380","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200400RR","volume":"37","author":"J Ren","year":"2023","unstructured":"Ren, J. et al. Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K\/AKT\/mTOR. FASEB J. 37, e22790 (2023).","journal-title":"FASEB J."},{"key":"2770_CR381","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1878-0261.12728","volume":"15","author":"Q Wu","year":"2021","unstructured":"Wu, Q. et al. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K\/AKT\/mTOR pathway. Mol. Oncol. 15, 299\u2013316 (2021).","journal-title":"Mol. Oncol."},{"key":"2770_CR382","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang, W. et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct. Target Ther. 5, 87 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2770_CR383","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct. Target Ther. 5, 298 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2770_CR384","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jare.2020.11.003","volume":"30","author":"C Guo","year":"2021","unstructured":"Guo, C. et al. 33-kDa ANXA3 isoform contributes to hepatocarcinogenesis via modulating ERK, PI3K\/Akt-HIF and intrinsic apoptosis pathways. J Adv. Res. 30, 85\u2013102 (2021).","journal-title":"J Adv. Res."},{"key":"2770_CR385","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tcm.2007.11.002","volume":"18","author":"I Fleming","year":"2008","unstructured":"Fleming, I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc. Med. 18, 20\u201325 (2008).","journal-title":"Trends Cardiovasc. Med."},{"key":"2770_CR386","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-018-0694-6","volume":"37","author":"J Luo","year":"2018","unstructured":"Luo, J. et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin \u03b1v\u03b23 and activating FAK\/PI3K\/AKT signaling. J. Exp. Clin. Cancer Res. 37, 23 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR387","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13046-021-02146-8","volume":"40","author":"H Li","year":"2021","unstructured":"Li, H. et al. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K\/AKT pathway. J. Exp. Clin. Cancer Res. 40, 340 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2770_CR388","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"key":"2770_CR389","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"2770_CR390","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10456-013-9376-3","volume":"17","author":"J Xiong","year":"2014","unstructured":"Xiong, J., Yang, Q., Li, J. & Zhou, S. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer. Angiogenesis 17, 37\u201350 (2014).","journal-title":"Angiogenesis"},{"key":"2770_CR391","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/onc.2011.174","volume":"30","author":"JH Park","year":"2011","unstructured":"Park, J. H. et al. Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1\u03b1 mediated by the PTEN\/PI3K\/Akt pathway. Oncogene 30, 4578\u20134589 (2011).","journal-title":"Oncogene"},{"key":"2770_CR392","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.1158\/0008-5472.CAN-08-2058","volume":"68","author":"Q Xue","year":"2008","unstructured":"Xue, Q. et al. Palomid 529, a novel small-molecule drug, is a TORC1\/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 68, 9551\u20139557 (2008).","journal-title":"Cancer Res."},{"key":"2770_CR393","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nrc2404","volume":"8","author":"G Neufeld","year":"2008","unstructured":"Neufeld, G. & Kessler, O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8, 632\u2013645 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"2770_CR394","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10456-020-09707-z","volume":"23","author":"J Cao","year":"2020","unstructured":"Cao, J. et al. Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS\/p53\/ BAI1 signaling pathway. Angiogenesis 23, 325\u2013338 (2020).","journal-title":"Angiogenesis"},{"key":"2770_CR395","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-132","volume":"11","author":"Y Su","year":"2013","unstructured":"Su, Y. et al. Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K\/Akt and NF-\u03baB\/MMP-2 signaling pathways. J. Transl. Med. 11, 132 (2013).","journal-title":"J. Transl. Med."},{"key":"2770_CR396","doi-asserted-by":"publisher","first-page":"117791","DOI":"10.1016\/j.jep.2024.117791","volume":"324","author":"JR Yu","year":"2024","unstructured":"Yu, J. R. et al. Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K\/Akt\/mTOR signaling pathway. J. Ethnopharmacol. 324, 117791 (2024).","journal-title":"J. Ethnopharmacol."},{"key":"2770_CR397","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cbi.2018.09.003","volume":"296","author":"D Sun","year":"2018","unstructured":"Sun, D. et al. 4\u2019-hydroxywogonin inhibits colorectal cancer angiogenesis by disrupting PI3K\/AKT signaling. Chem. Biol. Interact. 296, 26\u201333 (2018).","journal-title":"Chem. Biol. Interact."},{"key":"2770_CR398","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bcp.2016.11.009","volume":"125","author":"P Thirusangu","year":"2017","unstructured":"Thirusangu, P. et al. A tumoural angiogenic gateway blocker, benzophenone-1B represses the HIF-1\u03b1 nuclear translocation and its target gene activation against neoplastic progression. Biochem. Pharmacol. 125, 26\u201340 (2017).","journal-title":"Biochem. Pharmacol."},{"key":"2770_CR399","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.intimp.2018.10.035","volume":"65","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP\/TIMP system, PI3K\/Akt\/mTOR signaling and HIF-1\u03b1 nuclear translocation. Int. Immunopharmacol. 65, 429\u2013437 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"2770_CR400","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"2770_CR401","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2770_CR402","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/tan.12898","volume":"88","author":"B Seliger","year":"2016","unstructured":"Seliger, B. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. HLA 88, 213\u2013220 (2016).","journal-title":"HLA"},{"key":"2770_CR403","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1152\/physiol.00034.2020","volume":"36","author":"GL Semenza","year":"2021","unstructured":"Semenza, G. L. Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors. Physiology 36, 73\u201383 (2021).","journal-title":"Physiology"},{"key":"2770_CR404","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/JCI123319","volume":"129","author":"RM Chabanon","year":"2019","unstructured":"Chabanon, R. M. et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J. Clin. Invest. 129, 1211\u20131228 (2019).","journal-title":"J. Clin. Invest."},{"key":"2770_CR405","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fonc.2018.00054","volume":"8","author":"T Menter","year":"2018","unstructured":"Menter, T. & Tzankov, A. Mechanisms of immune evasion and immune modulation by lymphoma cells. Front. Oncol. 8, 54 (2018).","journal-title":"Front. Oncol."},{"key":"2770_CR406","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen, J., Jiang, C. C., Jin, L. & Zhang, X. D. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27, 409\u2013416 (2016).","journal-title":"Ann. Oncol."},{"key":"2770_CR407","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2770_CR408","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer. 21, 28 (2022).","journal-title":"Mol. Cancer."},{"key":"2770_CR409","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q., Han, J., Yang, Y. & Chen, Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front. Immunol. 13, 1070961 (2022).","journal-title":"Front. Immunol."},{"key":"2770_CR410","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1940-6207.CAPR-21-0572","volume":"15","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas. Cancer Prev. Res. 15, 285\u2013296 (2022).","journal-title":"Cancer Prev. Res."},{"key":"2770_CR411","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2019.12.009","volume":"471","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Acetylcholine promotes the self-renewal and immune escape of CD133+ thyroid cancer cells through activation of CD133-Akt pathway. Cancer Lett. 471, 116\u2013124 (2020).","journal-title":"Cancer Lett."},{"key":"2770_CR412","doi-asserted-by":"publisher","first-page":"115955","DOI":"10.1016\/j.biopha.2023.115955","volume":"170","author":"C Guo","year":"2024","unstructured":"Guo, C. et al. FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomed. Pharmacother. 170, 115955 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"2770_CR413","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ejca.2013.12.019","volume":"50","author":"A Riches","year":"2014","unstructured":"Riches, A., Campbell, E., Borger, E. & Powis, S. Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway. Eur. J. Cancer. 50, 1025\u20131034 (2014).","journal-title":"Eur. J. Cancer."},{"key":"2770_CR414","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/cgt.2014.80","volume":"22","author":"YF Fu","year":"2015","unstructured":"Fu, Y. F., Gui, R. & Liu, J. HER-2-induced PI3K signaling pathway was involved in the pathogenesis of gastric cancer. Cancer Gene Ther. 22, 145\u2013153 (2015).","journal-title":"Cancer Gene Ther."},{"key":"2770_CR415","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.7150\/ijbs.57964","volume":"17","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer. Int. J. Biol. Sci. 17, 1671\u20131681 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2770_CR416","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra, R. et al. PI3K inhibitors in cancer: clinical implications and adverse effects. Int. J. Mol. Sci. 22, 3464 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2770_CR417","doi-asserted-by":"publisher","first-page":"105900","DOI":"10.1016\/j.phrs.2021.105900","volume":"173","author":"D Meng","year":"2021","unstructured":"Meng, D. et al. Development of PI3K inhibitors: advances in clinical trials and new strategies (Review). Pharmacol. Res. 173, 105900 (2021).","journal-title":"Pharmacol. Res."},{"key":"2770_CR418","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","volume":"5","author":"P Panayiotidis","year":"2021","unstructured":"Panayiotidis, P. et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv. 5, 823\u2013828 (2021).","journal-title":"Blood Adv."},{"key":"2770_CR419","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik, A. et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann. Oncol. 27, 1928\u20131940 (2016).","journal-title":"Ann. Oncol."},{"key":"2770_CR420","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar, M. J. et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 678\u2013689 (2021).","journal-title":"Lancet Oncol."},{"key":"2770_CR421","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller, T. W. et al. ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 1, 338\u2013351 (2011).","journal-title":"Cancer Discov."},{"key":"2770_CR422","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/1078-0432.CCR-15-1745","volume":"22","author":"CX Ma","year":"2016","unstructured":"Ma, C. X. et al. A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin. Cancer Res. 22, 1583\u20131591 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR423","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro, A. C. et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 22, 120 (2020).","journal-title":"Breast Cancer Res."},{"key":"2770_CR424","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo, A. et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 87\u2013100 (2018).","journal-title":"Lancet Oncol."},{"key":"2770_CR425","doi-asserted-by":"publisher","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","volume":"65","author":"EJ Hanan","year":"2022","unstructured":"Hanan, E. J. et al. Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1. J. Med. Chem. 65, 16589\u201316621 (2022).","journal-title":"J. Med. Chem."},{"key":"2770_CR426","doi-asserted-by":"publisher","first-page":"196ra199","DOI":"10.1126\/scitranslmed.3005747","volume":"5","author":"M Elkabets","year":"2013","unstructured":"Elkabets, M. et al. mTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5, 196ra199 (2013).","journal-title":"Sci. Transl. Med."},{"key":"2770_CR427","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04206-5","volume":"12","author":"H Xu","year":"2021","unstructured":"Xu, H. et al. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death Dis. 12, 920 (2021).","journal-title":"Cell Death Dis."},{"key":"2770_CR428","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27599","volume":"10","author":"Y Li","year":"2024","unstructured":"Li, Y., Li, H. & Xiang, Z. Alpelisib-related adverse events: the FDA adverse event reporting system database (FAERS) pharmacovigilance study. Heliyon 10, e27599 (2024).","journal-title":"Heliyon"},{"key":"2770_CR429","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/2159-8290.CD-23-0945","volume":"13","author":"AL Kearney","year":"2023","unstructured":"Kearney, A. L. & Vasan, N. A new wave of PI3K\u03b1 inhibitors. Cancer Discov. 13, 2313\u20132315 (2023).","journal-title":"Cancer Discov."},{"key":"2770_CR430","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","volume":"23","author":"J Mateo","year":"2017","unstructured":"Mateo, J. et al. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 23, 5981\u20135992 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR431","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1158\/1078-0432.CCR-21-1115","volume":"27","author":"D Sarker","year":"2021","unstructured":"Sarker, D. et al. A phase I, open-label, dose-finding study of GSK2636771, a PI3K\u03b2 inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 5248\u20135257 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR432","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1158\/1078-0432.CCR-17-0676","volume":"23","author":"JT Lynch","year":"2017","unstructured":"Lynch, J. T. et al. Inhibiting PI3K\u03b2 with AZD8186 regulates key metabolic pathways in PTEN-null tumors. Clin. Cancer Res. 23, 7584\u20137595 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR433","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-21-3087","volume":"28","author":"AD Choudhury","year":"2022","unstructured":"Choudhury, A. D. et al. A phase I study investigating AZD8186, a potent and selective inhibitor of PI3K\u03b2\/\u03b4, in patients with advanced solid tumors. Clin. Cancer Res. 28, 2257\u20132269 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR434","doi-asserted-by":"publisher","first-page":"e823","DOI":"10.1093\/oncolo\/oyad059","volume":"28","author":"KJ Suh","year":"2023","unstructured":"Suh, K. J. et al. AZD8186 in combination with paclitaxel in patients with advanced gastric cancer: results from a phase Ib\/II study (KCSG ST18-20). Oncologist 28, e823\u2013e834 (2023).","journal-title":"Oncologist"},{"key":"2770_CR435","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","volume":"128","author":"C Belli","year":"2023","unstructured":"Belli, C. et al. The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br. J. Cancer 128, 2150\u20132162 (2023).","journal-title":"Br. J. Cancer"},{"key":"2770_CR436","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham, A. Idelalisib: first global approval. Drugs 74, 1701\u20131707 (2014).","journal-title":"Drugs"},{"key":"2770_CR437","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2770_CR438","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman, J. P. et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J. Clin. Oncol. 37, 1391\u20131402 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2770_CR439","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","volume":"83","author":"S Duggan","year":"2023","unstructured":"Duggan, S. & Al-Salama, Z. T. Leniolisib: first approval. Drugs 83, 943\u2013948 (2023).","journal-title":"Drugs"},{"key":"2770_CR440","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","volume":"143","author":"CJ Nunes-Santos","year":"2019","unstructured":"Nunes-Santos, C. J., Uzel, G. & Rosenzweig, S. D. PI3K pathway defects leading to immunodeficiency and immune dysregulation. J. Allergy Clin. Immunol. 143, 1676\u20131687 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2770_CR441","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","volume":"211","author":"CL Lucas","year":"2014","unstructured":"Lucas, C. L. et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J. Exp. Med. 211, 2537\u20132547 (2014).","journal-title":"J. Exp. Med."},{"key":"2770_CR442","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao, V. K. et al. A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood 141, 971\u2013983 (2023).","journal-title":"Blood"},{"key":"2770_CR443","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","volume":"153","author":"VK Rao","year":"2024","unstructured":"Rao, V. K. et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J. Allergy Clin. Immunol. 153, 265\u2013274 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2770_CR444","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/med.21770","volume":"41","author":"J Zhu","year":"2021","unstructured":"Zhu, J. et al. Targeting phosphatidylinositol 3-kinase gamma (PI3K\u03b3): Discovery and development of its selective inhibitors. Med. Res. Rev. 41, 1599\u20131621 (2021).","journal-title":"Med. Res. Rev."},{"key":"2770_CR445","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41401-023-01166-8","volume":"45","author":"DY Gu","year":"2024","unstructured":"Gu, D. Y. et al. Development of PI3K\u03b3 selective inhibitors: the strategies and application. Acta Pharmacol. Sin. 45, 238\u2013247 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"2770_CR446","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","volume":"7","author":"CA Evans","year":"2016","unstructured":"Evans, C. A. et al. Discovery of a selective phosphoinositide-3-kinase (PI3K)-\u03b3 inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med. Chem. Lett. 7, 862\u2013867 (2016).","journal-title":"ACS Med. Chem. Lett."},{"key":"2770_CR447","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial. Clin. Cancer Res. 29, 2210\u20132219 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR448","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/blood.2019001795","volume":"134","author":"K Patel","year":"2019","unstructured":"Patel, K., Danilov, A. V. & Pagel, J. M. Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma. Blood 134, 1573\u20131577 (2019).","journal-title":"Blood"},{"key":"2770_CR449","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair, H. A. Duvelisib: first global approval. Drugs 78, 1847\u20131853 (2018).","journal-title":"Drugs"},{"key":"2770_CR450","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn, I. W. et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132, 2446\u20132455 (2018).","journal-title":"Blood"},{"key":"2770_CR451","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41375-020-01010-6","volume":"35","author":"MS Davids","year":"2021","unstructured":"Davids, M. S. et al. A phase 1b\/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia 35, 1064\u20131072 (2021).","journal-title":"Leukemia"},{"key":"2770_CR452","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1038\/onc.2008.246","volume":"27","author":"C Garcia-Echeverria","year":"2008","unstructured":"Garcia-Echeverria, C. & Sellers, W. R. Drug discovery approaches targeting the PI3K\/Akt pathway in cancer. Oncogene 27, 5511\u20135526 (2008).","journal-title":"Oncogene"},{"key":"2770_CR453","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai, S. et al. The relation between PI3K\/AKT signalling pathway and cancer. Gene 698, 120\u2013128 (2019).","journal-title":"Gene"},{"key":"2770_CR454","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbcan.2018.08.001","volume":"1870","author":"M McKenna","year":"2018","unstructured":"McKenna, M., McGarrigle, S. & Pidgeon, G. P. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochim. Biophys. Acta Rev. Cancer. 1870, 185\u2013197 (2018).","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"key":"2770_CR455","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1002\/cncr.30286","volume":"122","author":"V Makker","year":"2016","unstructured":"Makker, V. et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer 122, 3519\u20133528 (2016).","journal-title":"Cancer"},{"key":"2770_CR456","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","volume":"22","author":"SO Dolly","year":"2016","unstructured":"Dolly, S. O. et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 22, 2874\u20132884 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR457","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2015.64.8808","volume":"34","author":"T Powles","year":"2016","unstructured":"Powles, T. et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K\/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 34, 1660\u20131668 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2770_CR458","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","volume":"17","author":"R Mallon","year":"2011","unstructured":"Mallon, R. et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR kinase inhibitor. Clin. Cancer Res. 17, 3193\u20133203 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR459","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1021\/jm901830p","volume":"53","author":"AM Venkatesan","year":"2010","unstructured":"Venkatesan, A. M. et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5\u2019-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem. 53, 2636\u20132645 (2010).","journal-title":"J. Med. Chem."},{"key":"2770_CR460","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00648-0","volume":"10","author":"S Rossetti","year":"2024","unstructured":"Rossetti, S. et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K\/AKT\/mTOR inhibitors in breast cancer models. NPJ Breast Cancer 10, 40 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"2770_CR461","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-21-1402","volume":"27","author":"I Colombo","year":"2021","unstructured":"Colombo, I. et al. Phase I dose-escalation study of the dual PI3K-mTORC1\/2 inhibitor gedatolisib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin. Cancer Res. 27, 5012\u20135019 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR462","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(24)00034-2","volume":"25","author":"RM Layman","year":"2024","unstructured":"Layman, R. M. et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 25, 474\u2013487 (2024).","journal-title":"Lancet Oncol."},{"key":"2770_CR463","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S1470-2045(25)00236-0","volume":"26","author":"RM Layman","year":"2025","unstructured":"Layman, R. M. et al. Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy. Lancet Oncol. 26, e332\u2013e333 (2025).","journal-title":"Lancet Oncol."},{"key":"2770_CR464","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-021-01137-8","volume":"14","author":"H Hua","year":"2021","unstructured":"Hua, H. et al. Targeting Akt in cancer for precision therapy. J. Hematol. Oncol. 14, 128 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2770_CR465","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani, A. S. PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside. Semin. Cancer Biol. 59, 125\u2013132 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"2770_CR466","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1517\/13543776.2011.587959","volume":"21","author":"ME Mattmann","year":"2011","unstructured":"Mattmann, M. E., Stoops, S. L. & Lindsley, C. W. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin. Ther. Pat. 21, 1309\u20131338 (2011).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2770_CR467","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-19-3953","volume":"26","author":"LM Smyth","year":"2020","unstructured":"Smyth, L. M. et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer. Clin. Cancer Res. 26, 3947\u20133957 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR468","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-22-2585","volume":"29","author":"D Pook","year":"2023","unstructured":"Pook, D. et al. A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29, 3292\u20133300 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2770_CR469","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1535-7163.MCT-15-0143","volume":"14","author":"R Ribas","year":"2015","unstructured":"Ribas, R. et al. AKT Antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo. Mol. Cancer Ther. 14, 2035\u20132048 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"2770_CR470","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","volume":"11","author":"BR Davies","year":"2012","unstructured":"Davies, B. R. et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11, 873\u2013887 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2770_CR471","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell, S. J. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 23, 851\u2013864 (2022).","journal-title":"Lancet Oncol."},{"key":"2770_CR472","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2770_CR473","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41416-020-0777-y","volume":"122","author":"EME Barnes","year":"2020","unstructured":"Barnes, E. M. E. et al. Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells. Br. J. Cancer. 122, 1298\u20131308 (2020).","journal-title":"Br. J. Cancer."},{"key":"2770_CR474","doi-asserted-by":"publisher","first-page":"104806","DOI":"10.1016\/j.phrs.2020.104806","volume":"156","author":"P Jabbarzadeh Kaboli","year":"2020","unstructured":"Jabbarzadeh Kaboli, P. et al. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - a comprehensive review from chemotherapy to immunotherapy. Pharmacol. Res. 156, 104806 (2020).","journal-title":"Pharmacol. Res."},{"key":"2770_CR475","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s10637-018-0591-z","volume":"36","author":"C Aghajanian","year":"2018","unstructured":"Aghajanian, C. et al. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest. New Drugs 36, 1016\u20131025 (2018).","journal-title":"Invest. New Drugs"},{"key":"2770_CR476","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/pcmr.12644","volume":"31","author":"AP Algazi","year":"2018","unstructured":"Algazi, A. P. et al. Dual MEK\/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 31, 110\u2013114 (2018).","journal-title":"Pigment Cell Melanoma Res."},{"key":"2770_CR477","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.19.01027","volume":"38","author":"AJ Chien","year":"2020","unstructured":"Chien, A. J. et al. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J. Clin. Oncol. 38, 1059\u20131069 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2770_CR478","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cncr.35103","volume":"130","author":"AL Ho","year":"2024","unstructured":"Ho, A. L. et al. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104). Cancer 130, 702\u2013712 (2024).","journal-title":"Cancer"},{"key":"2770_CR479","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1154-8","volume":"21","author":"Y Xing","year":"2019","unstructured":"Xing, Y. et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation. Breast Cancer Res. 21, 78 (2019).","journal-title":"Breast Cancer Res."},{"key":"2770_CR480","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ijc.32783","volume":"147","author":"AP Myers","year":"2020","unstructured":"Myers, A. P. et al. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int. J. Cancer 147, 413\u2013422 (2020).","journal-title":"Int. J. Cancer"},{"key":"2770_CR481","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"H Hirai","year":"2010","unstructured":"Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956\u20131967 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2770_CR482","doi-asserted-by":"publisher","first-page":"1235285","DOI":"10.3389\/fphar.2023.1235285","volume":"14","author":"HL Gao","year":"2023","unstructured":"Gao, H. L. et al. The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells. Front. Pharmacol. 14, 1235285 (2023).","journal-title":"Front. Pharmacol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02770-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:02:40Z","timestamp":1788134560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02770-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":482,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02770-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"353"}}